Subject index from vol 109 to 113 2002

Psychiatry Research 113 Ž2002. 317᎐340

Subject Index, Vols. 109᎐113, 2002 Acute stress disorder nitric oxide, plasma samples in earthquake rescue workers in Taiwan, 112:59 Adrenocorticotropic hormone lactate, panic attacks elicited in patients with panic disorder, 109:201 panic attacks in response to lactate in patients with panic disorder, 109:201 panic disorder, panic attacks in response to lactate, 109:201 Affective disorder. See Depression Age Center for Epidemiologic Studies-Depression Scale, elderly African-Americans, 109:61 elderly African-Americans, Center for Epidemiologic Studies-Depression Scale, 109:61 expressed emotion, schizophrenia, effects of patient’s age on family communication patterns, 109:161 schizophrenia, effects of patient’s age on family communication patterns, expressed emotion, 109:161 Aggression Overt Aggression Scale-Modified, assessment of interrater reliability, ratings of actors portraying different forms of personality disorder, 112:153 Alcoholism brain injury, associated with alcoholism in Northern Finland Birth Cohort Study, 113:217 childhood psychopathology preceding onset of alcohol dependence, 109:245 emotion, attention direction and measures of facial affect perception, 113:161 epidemiology, alcohol dependence related to traumatic brain injury in Northern Finland Birth Cohort Study, 113:217 facial affect perception, attention direction, 113:161 genetics, monoamine oxidase A promoter polymorphism in Finnish male alcoholics, 109:113 genetics, norepinephrine transporter gene polymorphism, not associated with susceptibility to alcohol abuse in German sample, 111:229 monoamine oxidase A promoter polymorphism, Finnish male alcoholics, 109:113 PII: S 0 1 6 5 - 1 7 8 1 Ž 0 2 . 0 0 3 1 3 - X

norepinephrine transporter gene polymorphism, not associated with susceptibility to alcohol abuse in German sample, 111:229 traumatic brain injury, associated with alcoholism in Northern Finland Birth Cohort Study, 113:217 Amisulpride dysthymic disorder, outcome and psychosocial function after paroxetine vs. paroxetine plus amisulpride, 112:145 Anhedonia anorexia and bulimia nervosa, fear of weight gain, response to sucrose solutions, 113:173 Anorectic Behavior Observation Scale factor analysis in Japanese vs. Belgian samples of relatives of patients with eating disorders, 111:241 information from relatives about behaviors and attitudes of patients with eating disorders, 111:241 Anthropometry abdominal obesity, depression and anxiety symptoms, cortisol, glucose and insulin levels, middle-aged male volunteers, 112:101 anxiety and depression symptoms, body mass index, waistrhip ratio in sample of middle-aged male volunteers, 112:101 anxiety and depression symptoms, cortisol, glucose, and insulin levels in middle-aged male volunteers abdominal obesity, 112:101 cortisol, abdominal obesity, anxiety and depression symptoms, 112:101 insulin and glucose, abdominal obesity, anxiety and depression symptoms in middle-aged male volunteers, 112:101 Antisocial personality disorder rapists and child molesters, testosterone levels, 110:239 testosterone levels, rapists and child molesters, 110:239 Anxiety abdominal obesity, relationship to anxiety and depression symptoms, cortisol, insulin and glucose in middle-aged male volunteers, 112:101 asthma, association with panic and agoraphobia spectrum disorders, 110:73

318

Subject Index

body mass index, depression and anxiety symptoms, cortisol, insulin and glucose in middle-aged male voluneers, 112:101 cortisol, abdominal obesity, depression and anxiety symptoms, middle-aged male volunteers, 112:101 cortisol, response to ipsapirone and meta-chlorophenylpiperazine, Spielberger State Anxiety Inventory, 113:29 cross-cultural, internal validity of National Anxiety Disorder Screening Day Instrument across five ethnic groups, 111:199 emotion, memory for facial expressions in depressed and anxious men and women, 113:279 heart rate, time-series analysis, largest Lyapunov exponents, lactate, isoproterenol, 109:81 insulin and glucose, abdominal obesity, anxiety and depression symptoms, middle-aged male volunteers, 112:101 ipsapirone, endocrine and anxiety responses in depressed patients, Spielberger State Anxiety Inventory, 113:29 isoproterenol, heart rate, time series analysis, largest Lyapunov exponents, 109:81 lactate, heart rate, time series analysis, largest Lyapunov exponents, 109:81 memory for facial expressions in depressed and anxious men and women, 113:279 meta-chlorophenylpiperazine, endocrine responses in depressed patients, Spielberger State Anxiety Inventory, 113:29 National Anxiety Disorder Screening Day Instrument, internal validity of screening instrument across five ethnic groups, 111:199 prolactin, responses to ipsapirone and meta-chlorophenylpiperazine, Spielberger State Anxiety Inventory, 113:29 screening for anxiety, National Anxiety Disorder Screening Day Instrument, 111:199 serotonin, responses to ipsapirone and meta-chlorophenylpiperazine, 113:29 Spielberger State Anxiety Inventory, endocrine responses to ipsapirone and meta-chlorophenylpiperazine, 113:29 Apathy cocaine abstinence syndrome, Neuropsychiatric Inventory Apathy Subscale, 109:97 Neuropsychiatric Inventory Apathy Subscale, cocaine abstinence syndrome, 109:97 Arginine vasopressin depressive disorder, sexual diergism in plasma leptin measures, 113:255 leptin, sexual diergism in plasma measures, depressive disorder, 113:255 sexual diergism in plasma leptin measures, depressive disorder, 113:255 Asthma anxiety, panicragoraphobic spectrum disorders, 110:73 Attention dichotic listening, laterality, schizophrenia, 109:281

laterality, dichotic listening, schizophrenia, 109:281 schizophrenia, dichotic listening, laterality, 109:281 Attention deficit hyperactivity disorder children with and without comorbid oppositional defiant disorder, electroencephalography, 111:181 electroencephalography, children with and without comorbid oppositional defiant disorder, 111:181 electroencephalography, quantitative analysis in adult patients, 112:133 Beck Depression Inventory-II factor analysis in Japanese visitors to public health care center, comparison with Center for Epidemiologic Studies-Depression Scale, 110:291 psychometric properties of Japanese version, comparison with Center for Epidemiologic Studies-Depression Scale, 110:291 Beta-thromboglobulin depressive disorder, post-myocardial infarction patients, 109:207 myocardial infarction, depression in cardiac patients, 109:207 Bipolar affective disorder agitation and retardation, psychomotor activity, unipolar and bipolar-II subtypes, 112:211 climate and sunlight variables, first manic episodes in Korea, 113:151 cross-national, Italy vs. The Netherlands, lithium plasma levels, 111:43 diagnosis, subtype comparisons, 112:211, 112:195 Life Functioning Questionnaire and Clinical Global Impression Scale for Bipolar Disorder, 112:161 lithium plasma levels, Italy vs. The Netherlands, 111:43 lithium plasma levels, seasonality, 111:35, 111:43 psychomotor activity, unipolar and bipolar-II subtypes, 112:211 seasonality, climate and sunlight variables, 113:151 seasonality, first manic episodes in Korea, 113:151 seasonality, lithium plasma levels, 111:35, 111:43 unipolar and bipolar-II subtypes, psychomotor activity, 112:211 Body dysmorphic disorder prevalence in German college students, self-report questionnaires assessing self-esteem, symptoms of depression and obsessive-compulsive disorder, skin picking, 109:101 Body image body image questionnaire in Taiwanese college students, sex differences in body-shape preference and satisfaction in men vs. women, 111:215 Body mass index abdominal obesity, anxiety and depression symptoms, cortisol, insulin and glucose, middle-aged male volunteers, 112:101

Subject Index anxiety and depression symptoms, abdominal obesity, cortisol, insulin and glucose, middle-aged male volunteers, 112:101 cortisol, abdominal obesity, anxiety and depression symptoms, middle-aged male volunteers, 112:101 insulin and glucose, abdominal obesity, anxiety and depression symptoms, middle-aged male volunteers, 112:101

319

China’s one-child policy Chinese university students, Plutchik-van Praag Depression Inventory, Zuckerman-Kuhlman Personality Questionnaire, 109:37 Chinese university students with and without siblings, birth order position within family and ruralrurban status, personality traits, depressed mood, 109:37

Brain injury. See Traumatic brain injury Bulimia. See Eating disorders Cannabis Chapman Psychosis Proneness Scales, schizotypal traits in students, 109:27 schizotypy, Schizotypal Personality Questionnaire, Chapman Psychosis Proneness Scales, Magical Ideation Subscale, 109:27 Catechol-O-methyltransferase gene eye movements, fixation and smooth-pursuit tests, schizophrenia, 113:49 schizophrenia, eye movements, fixation and smooth-pursuit tests, 113:49 Center for Epidemiologic Studies-Depression Scale (CES-D) correlated with Beck Depression Inventory-II in Japanese visitors to public health care center, 110:291 depressive symptoms, differential item functioning analysis, racialrethnic groups, 110:281 factor analysis, measurement adequacy among a sample of elderly African-Americans, 109:61 Chapman Psychosis Proneness Scales cannabis use, schizotypal traits, Magical Ideation Subscale scores, 109:27 schizotypy, cannabis use, Magical Ideation Subscale scores, 109:27 Child rearing epidemiology, influences of parenting on personality traits in community sample, 111:55 Parental Bonding Instrument, influences of parenting on personality traits in community sample, 111:55 personality traits, influences of parenting, 111:55 Revised NEO Personality Inventory, influences of parenting, 111:55 Temperament and Character Inventory, influences of parenting, 111:55 Childhood-onset psychopathology history of childhood disorder preceding alcoholism, opioid dependence in adults, 109:245 Children Temperament and Character Inventory, preschool version, seven-factor model of personality, 109:229

Cholecystokinin tetrapeptide panicogenic effects in healthy men related to high vs. low trait dissociation, 111:93 Cholesterol Beck Depression Inventory, mood symptoms in late pregnancy and postpartum period, sample of healthy primaparous women, 109:213 depressive symptoms, in late pregnancy and postpartum period, sample of healthy primaparous women, 109:213 novelty seeking on Temperament and Character Inventory, psychiatric inpatients with and without suicidal behavior, 112:83 personality scores on the Temperament and Character Inventory in psychiatric inpatients with and without suicide attempts, 112:83 postpartum symptoms of depression, Beck Depression Inventory, sample of healthy primaparous women, 109:213 suicide, psychiatric inpatients with and without suicide attempts, Temperament and Character Inventory, 112:83 Temperament and Character Inventory, psychiatric inpatients with and without suicide attempts, 112:83

Circadian rhythm sleep disorders Clock gene, mutation screening in patients with delayed sleep phase syndrome, non-24-hour sleep-wake syndrome, 109:121 sleep, Clock gene, mutation screening in patients with delayed sleep phase syndrome, non-24-hour sleep-wake syndrome, 109:121 Clock gene. See Circadian rhythm sleep disorders; Genetics

Clomipramine Positive and Negative Syndrome Scale, schizophrenia, prolactin response, duration of illness, haloperidol treatment, 110:9 prolactin response, duration of illness, changes in Positive and Negative Syndrome Scale, 110:9 schizophrenia, prolactin response, duration of illness, Positive and Negative Syndrome Scale, haloperidol treatment, 110:9 Clonazepam panic disorder, carbon dioxide challenge test may predict clinical response, 112:269

320

Subject Index

Clonidine cortisol response to clonidine challenge, posttraumatic stress disorder vs. panic disorder, 110:219 depressive disorder, sleep, blunted REM sleep response to clonidine normalized by mirtazapine but not fluvoxamine, 109:1 fluvoxamine, fails to normalize blunted REM sleep response to clonidine in depressive disorder despite clinical recovery, 109:1 mirtazapine, depressive disorder, normalizes blunted REM sleep response to clonidine, 109:1 norepinephrine, panic disorder vs. posttraumatic stress disorder, 3-methoxy-4-hydroxyphenolglycol response to clonidine challenge 110:219 panic disorder vs. posttraumatic stress disorder, cortisol and 3-methoxy-4-hydroxyphenolglycol response to clonidine challenge 110:219 posttraumatic stress disorder vs. panic disorder, cortisol and 3-methoxy-4-hydroxyphenolglycol response to clonidine challenge, 110:219 sleep, depressive disorder, blunted REM sleep response to clonidine normalized by mirtazapine but not fluvoxamine, 109:1

Clozapine hippocampal HT22 cells, serotonergic effects in schizophrenia, 112:221 schizophrenia, hippocampal HT22 cells, serotonergic effects in schizophrenia, 112:221 serotonin, effects of clozapine on hippocampal HT22 cells in schizophrenia, 112:221 r dependence Cocaine abuser African-American cocaine-dependent sample, serotonin transporter polymorphisms, impulsivity and aggression, 110:103 apathy syndrome, cocaine abstinence syndrome, Neuropsychiatric Inventory Apathy Subscale, 109:97 Childhood Trauma Questionnaire, abstinent cocaine-abusing adults, self-rated childhood emotional neglect, cerebrospinal fluid levels of 5-hydroxyindoleacetic acid and homovanillic acid, 112:69 cocaine abstinence syndrome, Neuropsychiatric Inventory Apathy Subscale, 109:97 dopamine, homovanillic acid in cerebrospinal fluid, Childhood Trauma Questionnaire, abstinent cocaine-abusing adults, self-rated childhood emotional neglect, 112:69 genetics, serotonin transporter polymorphisms, AfricanAmerican cocaine-dependent sample, 109:97 homovanillic acid in cerebrospinal fluid, Childhood Trauma Questionnaire, abstinent cocaine-abusing adults, self-rated childhood emotional neglect, 112:69 impulsivity and aggression, African-American cocaine-dependent sample, serotonin transporter polymorphisms, 110:103 Neuropsychiatric Inventory Apathy Subscale, cocaine abstinence syndrome, 109:97

personality, African-American cocaine-dependent sample, impulsivity and aggression, serotonin transporter polymorphisms, 110:103 serotonin, 5-hydroxyindoleacetic acid in cerebrospinal fluid, Childhood Trauma Questionnaire, abstinent cocaine-abusing adults, self-rated childhood emotional neglect, 112:69 serotonin transporter polymorphisms, African-American cocaine-dependent sample, impulsivity and aggression, 110:103

Cognition anxiety, memory for facial expressions, 113:279 apathy and disinhibition, Frontal Systems Behavior Scale, schizophrenia, 113:227 California Verbal Learning Test, schizophrenia, 112:13, 113:93 depressive disorder, memory for facial expressions, 113:279 disorganized symptoms, working memory and executive function, schziophrenia, 113:83 early intervention program in first episode schizophrenia, changes in memory and executive function, 113:69 emotion, memory for facial expressions in anxious and depressed subjects, 113:279 Frontal Systems Behavior Scale, apathy and disinhibition, schizophrenia, 113:227 memory, California Verbal Learning Test, 113:93 memory, disorganized symptoms, 113:83 memory for facial expressions in subjects with anxiety and depression, 113:279 memory-impaired subtype of schizophrenia, California Verbal Learning Test, 113:93 memory-impaired subtype of schizophrenia, quality of life and positive symptoms, 113:93 memory, quality of life and positive symptoms of schizophrenia, 113:93 memory, schizophrenia, 110:259, 113:83, 113:93 memory, self-ordered pointing task, 110:259 memory, spatial working memory span, 110:259 memory, working memory and executive function, 113:83 methamphetamine dependence, Stroop test, 111:65 motion perception and working memory, schizophrenia, 111:125 motion perception and working memory, visual psychophysical tests and neuropsychological function, 111:125 neuropsychological test battery, thyroxine, 110:117 neuropsychological tests, executive function, schizotypy, 110:151 neuropsychological tests, obsessive-compulsive characteristics, 110:151 obsessive-compulsive characteristics, executive function, 110:151 obsessive-compulsive characteristics, neuropsychological tests, 110:151 obsessive-compulsive disorder, executive function, 110:165 obsessive-compulsive disorder, go-no go task, Stroop task, 110:165

Subject Index perceptual organization, schizophrenia, Stroop task, top-down processing, 110:125 posttraumatic stress disorder, semantic processing of traumarelevant words, 113:303 posttraumatic stress disorder, sentence completion test, 113:303 psychomotor poverty subsyndrome, schizophrenia, 112:13 quality of life and positive symptoms, Sickness Impact Profile, schizophrenia, 113:93 schizophrenia, apathy and disinhibition, 113:227 schizophrenia, California Verbal Learning Test, 112:13, 113:93 schizophrenia, changes in memory and executive function, 113:69 schizophrenia, cognitively normal vs. cognitively impaired subgroup, 112:1 schizophrenia, disorganized symptoms, 113:83 schizophrenia, early intervention program in first episodes, 113:69 schizophrenia, executive function, 113:227 schizophrenia, Frontal Systems Behavior Scale, 113:227 schizophrenia, memory, 110:259, 113:83, 113:93 schizophrenia, memory-impaired subtype, 113:93 schizophrenia, motion perception and working memory, 111:125 schizophrenia, perceptual organization, 110:125 schizophrenia, Positive and Negative Syndrome Scale, 112:13 schizophrenia, psychomotor poverty subsyndrome, 112:13 schizophrenia, quality of life and positive symptoms, 113:93 schizophrenia, self-ordered pointing task, 110:259 schizophrenia, Sickness Impact Profile, 113:93 schizophrenia, social functioning and educational level, 112:1 schizophrenia, social functioning and symptomatology, 113:227 schizophrenia, spatial working memory span, 110:259 schizophrenia, Stroop task, 110:125, 110:137 schizophrenia, tasks requiring use of a rule, 109:289 schizophrenia, top-down processing, 110:125 schizophrenia, visual psychophysical tests and neuropsychological function, 111:125 schizophrenia, Wisconsin Card Sorting Test, perseveration, 112:13 schizophrenia, working memory and executive function, 113:83 schizotypy, executive function, neuropsychological tests, 110:151 schizotypy, obsessive-compulsive characteristics, 110:151 semantic processing of trauma-relevant words, sentence completion test, posttraumatic stress disorder, 113:303 Sickness Impact Profile, memory-impaired subtype of schizophrenia, 113:93 social functioning and educational level, cognitively normal vs. cognitively impaired subgroups of schizophrenia, 112:1 social functioning and symptomatology, schizophrenia, Frontal Systems Behavior Scale, 113:227 spatial working memory span, schizophrenia, self-ordered pointing task, 110:259 Stroop test, methamphetamine dependence, 111:65 Stroop task, schizophrenia, 110:125, 110:137 tasks requiring use of a rule, schizophrenia, 109:289

321

thyroxine, cognition, effects of supraphysiological doses on function as assessed with neuropsychological test battery, 110:117 top-down processing, schizophrenia, 110:125 visual psychophysical tests, motion perception and working memory, neuropsychological, schizophrenia, 111:125 Wisconsin Card Sorting Test perseveration, schizophrenia, Positive and Negative Syndrome Scale, 112:13 working memory and executive function, schizophrenia, disorganized symptoms, 113:83 Cortisol abdominal obesity, anxiety and depression, 112:101 anticipatory stress response, salivary cortisol in sons and daughters of drug abusers, 112:121 anxiety, abdominal obesity, 112:101 anxiety, ipsapirone and meta-chlorophenylpiperazine challenge, 113:29 body mass index, anxiety and depression, 112:101 body mass index, insulin and glucose, 112:101 clonidine challenge, panic disorder and posttraumatic stress disorder, 110:219 depression, abdominal obesity, 112:101 depressive disorder, dexamethasone, 113:1 depressive disorder, immune factors, 113:1 depressive disorder, ipsapirone challenge, 113:29 depressive disorder, lymphocyte distribution and expression of adhesion molecules, 113:1 depressive disorder, meta-chlorophenylpiperazine challenge, 113:29 dexamethasone, depressive disorder, immune factors, lymphocyte distribution and expression of adhesion molecules, 113:1 drug abuse, salivary cortisol in sons and daughters of drug abusers, 112:121 immune factors, lymphocyte distribution and expression of adhesion molecules, depressive disorder, 113:1 insomnia, nocturnal endocrine measures in primary insomnia, polysomnography, 113:17 ipsapirone challenge, anxiety and depressive disorder, 113:29 lymphocyte distribution and expression of adhesion molecules, dexamethasone, depressive disorder, 113:1 meta-chlorophenylpiperazine challenge, anxiety and depressive disorder, 113:29 nocturnal endocrine measures in primary insomnia, polysomnography, 113:17 panic disorder, clonidine challenge, 110:219 polysomnography, insomnia, nocturnal endocrine measures in primary insomnia, 113:17 posttraumatic stress disorder, clonidine challenge, 110:219 salivary cortisol in sons and daughters of drug abusers, anticipatory stress response, 112:121 sex difference, anticipatory stress response, salivary cortisol in sons and daughters of drug abusers, 112:121 sleep, insomnia, nocturnal endocrine measures in primary insomnia, polysomnography, 113:17 stress, anticipatory response, salivary cortisol in sons and daughters of drug abusers, 112:121

322

Subject Index

Criminality traumatic brain injury, Northern Finland Birth Cohort Study, 113:217 Cross-cultural Anorectic Behavior Observation Scale, factor analysis in Japanese vs. Belgian samples, 111:241 anxiety disorder, National Anxiety Disorder Screening Day Instrument, internal validity across five ethnic groups, 111:199 eating disorder, factor analysis of Anorectic Behavior Observation Scale in Japanese vs. Belgian samples, 111:241 magical ideation and olfactory sensitivity, German and Japanese healthy subjects, 111:21 National Anxiety Disorder Screening Day Instrument, internal validity of screening instrument across five ethnic groups, 111:199 olfactory experiences, magical ideation, German and Japanese healthy subjects, 111:21 quality of life, reliability and validity of Japanese version of Schizophrenia Quality of Life Scale, 113:107 schizophrenia, Japanese version of Schizophrenia Quality of Life Scale, 113:107 schizotypy, magical ideation, olfactory experiences, German and Japanese healthy subjects, 111:21 Cross-National bipolar affective disorder, seasonality of lithium plasma levels, Italy vs. Netherlands, 111:43 depressive disorder, seasonality of lithium plasma levels, Italy vs. Netherlands, 111:43 lithium plasma levels, seasonality, bipolar affective disorder and major depression, Italy vs. Netherlands, 111:43 seasonality, lithium plasma levels, Italy vs. Netherlands, 111:43 Dementia frontotemporal lobar degeneration, Stereotypy Rating Inventory, 110:175 Stereotypy Rating Inventory, frontotemporal lobar degeneration, 110:175 Depression abdominal obesity, cortisol, insulin and glucose, symptoms of depression in middle-aged male volunteers, 112:101 agitation and retardation, frequency in atypical, bipolar-II, unipolar and melancholic subtypes, 112:211 alpha-2 adrenergic receptors, clonidine REM suppression test, blunted response in depressed patients normalized by mirtazapine but not fluvoxamine, 109:1 anthropometry, cortisol, insulin and glucose, symptoms of depression in middle-aged male volunteers, 112:101 antidepressant response to fluvoxamine, serotonin transporter gene, 111:235 arginine vasopressin, sexual diergism of leptin suppression in major depressives, 113:255 atypical depression, frequency of agitation and retardation, 112:211

atypical depression, seasonality, failure to find higher rates in winter, 112:187 Beck Depression Inventory, cholesterol, post-partum depression symptoms in sample of healthy primaparous women, 109:213 beta-thromboglobulin and platelet factor 4 after mycardial infarction, depression in cardiac patients, 109:207 bipolar affective disorder, demographic and clinical features of depression subtypes, 112:195 bipolar affective disorder, frequency of agitation and retardation, 112:211 bipolar affective disorder, Life Functioning Questionnaire, 112:161 bipolar affective disorder, seasonality of plasma lithium levels, 111:35, 111:43 body mass index, cortisol, insulin and glucose, depression symptoms in middle-aged male volunteers, 112:101 case identification, Diagnostic Inventory for Depression, selfreport screening questionnaire, 109:51 Center for Epidemiologic Studies-Depression Scale, cholesterol, postpartum depression, 109:213 Center for Epidemiologic Studies-Depression Scale, differential item functioning analysis, racerethnicity, 110:281 cholesterol, post-partum depressed symptoms in sample of healthy primaparous women, 109:213 clonidine REM suppression test, blunted response in depressed patients normalized by mirtazapine but not fluvoxamine, 109:1 cortisol, abdominal obesity, depression symptoms in middleaged male volunteers, 112:101 cortisol, dexamethasone, immune factors, treatment-resistant depression, 113:1 cortisol, ipsapirone vs. meta-chlorophenylpiperazine challenge, 113:29 cortisol, lymphocyte distribution and expression of adhesion molecules in treatment-resistant depression, 113:1 cross-national, Italy vs. The Netherlands, seasonality of lithium plasma levels, 111:43 depression in medical patients after myocardial infarction, platelet factor 4, beta-thromboglobulin, 109:207 depression severity, serum brain-derived neurotrophic factor, 109:143 dexamethasone, cortisol, immune factors, treatment-resistant depression, 113:1 dexamethasone, lymphocyte distribution and expression of adhesion molecules, 113:1 diagnosis and clinical characteristics of depression subtypes, 112:195, 112:211 Diagnostic Inventory for Depression, self-report screening questionnaire, 109:51 disorder severity in first episodes of depression vs. schizophrenia, expressed emotion determined by Five-Minute Speech Sample, 111:155 electroencephalography, effect of subthreshold stimulation course of transcranial magnetic stimulation, 113:245 emotion, memory for facial expressions in depressed men vs. women, 113:279

Subject Index epinephrine, guanine nucleotide-binding regulatory proteins, GTPase activity in platelet membranes, 112:111 ethnicityrrace, Center for Epidemiologic Studies-Depression Scale, differential item functioning analysis, 110:281 ethology, nonverbal interaction involvement, observational ratings of patient-interviewer dyads, outcome prediction, 113:269 expressed emotion, disorder severity in first episodes, 111:155 expressed emotion, Five-Minute Speech Sample, 111:155, 112:231, 112:239 expressed emotion, validity of Five-Minute Speech Sample in families of Japanese patients with mood disorders, 112:231 Eysenck Personality Questionnaire, relationship of personality to prolactin response to fenfluramine in depressed men, 109:221 fenfluramine, Eysenck Personality Questionnaire, Tridimensional Personality Questionnaire, 109:221 fenfluramine, prolactin response, relationship to personality and temperament in depressed men, 109:221 fluoxetine, clinical response, neuroticism score on NEO FiveFactor Personality Inventory, 109:9 fluvoxamine fails to reverse blunted response to clonidine REM suppression test, 109:1 fluvoxamine, serotonin transporter gene, antidepressant response, 111:235 genetics, antidepressant response to fluvoxamine, serotonin transporter gene, 111:235 GTPase activity in platelet membranes, guanine nucleotidebinding regulatory proteins, epinephrine and thrombin stimulation, 112:111 guanine nucleotide-binding regulatory proteins, GTPase activity in platelet membranes, epinephrine and thrombin stimulation, 112:111 heart rate variability, severity of symptoms and modulation of cardiovagal activity, 113:139 immune factors, cortisol response to dexamethasone, treatment-resistant depression, 113:1 immune factors, lymphocyte distribution and expression of adhesion molecules, 113:1 insulin and glucose, abdominal obesity, depression symptoms in middle-aged male volunteers, 112:101 ipsapirone vs. meta-chlorophenylpiperazine, cortisol and prolactin response, 113:29 leptin, arginine vasopressin, sexual diergism in plasma leptin measures, 113:255 Life Functioning Questionnaire, bipolar affective disorder, 112:161 lithium, bipolar affective disorder, 111:35, 111:43 lithium, combined lithium plus clomipramine treatment, interaction of lithium with 5-HT1B receptors, 111:117 lithium, seasonality of plasma levels, 111:35, 111:43 lymphocyte distribution and expression of adhesion molecules, cortisol, dexamethasone, immune factors, 113:1 melancholic subtype, frequency of agitation and retardation, 112:211 memory for facial expressions, depressed men vs. women, 113:279

323

meta-chlorophenylpiperazine, cortisol and prolactin responses, 113:29 mirtazapine, clonidine REM suppression test, 109:1 myocardial infarction, beta-thromboglobulin, platelet factor 4, depression in cardiac patients, 109:207 myocardial infarction, platelet factor 4, 109:207 NEO Five-Factor Personality Inventory, neuroticism score, clinical response to fluoxetine, 109:9 neuroticism, NEO Five-Factor Personality Inventory, response to fluoxetine, 109:9 neurotrophic factor, depression severity, 109:143 nonverbal interaction involvement, observational ratings of patient-interviewer dyads, outcome, 113:269 outcome, personality changes with recovery, 109:17 outcome prediction, nonverbal interaction involvement, 113:269 outcome prediction, observational ratings of patient-interviewer dyads, 113:269 outcome, Temperament and Character Inventory, 109:17 personality changes with recovery, outcome, 109:17 personality changes with recovery, Temperament and Character Inventory, Eysenck Personality Questionnaire, 109:221 personality, fluoxetine, NEO Five-Factor Personality Inventory, neuroticism score, outcome, 109:9 personality, prolactin response to fenflurame, 109:221 personality, Temperament and Character Inventory, 109:17 personality, Tridimensional Personality Questionnaire, 109:221 platelet factor 4, beta-thromboglobulin, depression in cardiac patients, 109:207 postpartum depression, cholesterol, Beck Depression Inventory, sample of healthy primaparous women, 109:213 prolactin, Eysenck Personality Questionnaire, 109:221 prolactin, response to fenfluramine, 109:221 prolactin, response to ipsapirone, 113:29 prolactin, response to meta-chlorophenylpiperazine, 113:29 prolactin, Tridimensional Personality Questionnaire, 109:221 psychomotor activity, agitation and retardation, frequency in depression subtypes, somewhat more common in melancholia, 112:211 season of birth, birth during peak flu season, Southern vs. Northern Hemispheres, 112:89 season of birth, suicide, 112:89 seasonality, atypical depression, 112:187 seasonality, bipolar affective disorder, 111:43, 111:35 seasonality, bulimia nervosa, 112:187 seasonality, lithium plasma levels, 111:35, 111:43 seasonality, suicidal ideation, 112:187 serotonin, combined lithium plus clomipramine treatment, interaction of lithium with 5-HT1B receptors, 111:117 serotonin, prolactin response to ipsapirone vs. meta-chlorophenylpiperazine challenges, 113:29 serotonin transporter gene, antidepressant response to fluvoxamine, 111:235 serum brain-derived neurotrophic factor, depression severity, 109:143

324

Subject Index

severity of symptoms and modulation of cardiovaga activity, heart rate variability, 113:139 sexual diergism in plasma leptin measures, arginine vasopressin, 113:255 sleep, alpha-2 adrenergic receptors, 109:1 sleep, clonidine REM suppression test, fluvoxamine vs. mirtazapine, 109:1 Southern vs. Northern Hemispheres, suicide, season of birth, 112:89 suicidal ideation, seasonality, 112:187 suicide, birth during peak flu season, 112:89 suicide, season of birth, Southern vs. Northern Hemispheres, 112:89 symptom profiles, utility scores, 110:189 Temperament and Character Inventory, personality changes with recovery, 109:17 thrombin, epinephrine, GTPase activity in platelet membranes, 112:111 thrombin, guanine nucleotide-binding regulatory proteins, 112:111 transcranial magnetic stimulation, effect of subthreshold stimulation course, electroencephalography, 113:245 Tridimensional Personality Questionnaire, prolactin response to fenfluramine, 109:221 unipolar and bipolar-II subtypes, agitation and retardation, 112:211 unipolar and bipolar-II subtypes, bipolar affective disorder, 112:211 utility scores, symptom profiles, 110:189 validity in Japanese families of depressed patients, Five-Minute Speech Sample as measure of expressed emotion, 112:231 vesicular monoamine transporter, density in platelets of untreated patients, 112:251 Dexamethasone cortisol, lymphocyte distribution and expression of adhesion molecules in treatment-resistant depression, 113:1 Diagnosis anxiety disorder screening instrument, internal validity across five ethnic groups, 111:199 bipolar affective disorder, demographic and clinical features of subtypes, 112:195 Computer Assisted Diagnostic Interview vs. Traditional Diagnostic Assessment, 111:191 depressive disorder, demographic and clinical features of subtypes, 112:195 depressive disorder, Diagnostic inventory for Depression, case identification with self-report screening questionnaire, 109:51 depressive disorder, psychomotor activity symptoms, frequency in subtypes, 112:211 Traditional Diagnostic Assessment vs. Computer Assisted Diagnostic Interview, 111:191 Dopamine Childhood Trauma Questionnaire, cocaine abuse, homovanillic acid, 112:69

cocaine abuse, self-rated childhood emotional neglect, homovanillic acid, 112:69 dopamine D2 receptor agonist, quinagolide, social phobia, prolactin response, 111:87 homovanillic acid, Childhood Trauma Questionnaire, selfrated childhood emotional neglect in cocaine abusers, 112:69 prolactin response to quinagolide, dopamine D2 receptor agonist, social phobia, 111:87 quinagolide, dopamine D2 receptor agonist, prolactin response in social phobia, 111:87 social phobia, dopamine D2 receptor agonist quinagolide, prolactin response, 111:87 r dependence; Drug abuse. See also Alcoholism; Cocaine abuser r dependence Substance abuser cortisol, anticipatory stress response in sons and daughters of drug abusers, 112:121 sex difference, anticipatory stress response, salivary cortisol response in sons and daughters of drug abusers, 112:121 Dysthymia amisulpride vs. paroxetine, outcome and psychosocial function, 112:145 Eating disorder anhedonia, fear of weight gain, response to sucrose solutions, 113:173 Anorectic Behavior Observation Scale, factor analysis in Japanese vs. Belgian samples, 111:241 anorexia nervosa, anhedonia, fear of weight gain, response to sucrose solutions, 113:173 anorexia nervosa, prevalence of drug use in Japanese patients, 109:181 bulimia nervosa, anhedonia, fear of weight gain, response to sucrose solutions, 113:173 bulimia nervosa, prevalence of drug use in Japanese patients, 109:181 bulimia nervosa, seasonality, 112:187 cross-cultural, Anorectic Behavior Observation Scale, factor analysis in Japanese vs. Belgian samples, 111:241 fear of weight gain, hedonic response to sucrose solutions, 113:173 hedonic response to sucrose solutions, fear of weight gain, 113:173 seasonality, bulimia nervosa, 112:187 substance dependence, prevalence of drug use in Japanese patients with eating disorders, 109:181 Electroencephalography attention deficit hyperactivity disorder in adults, quantitative EEG analysis, 112:133 attention deficit hyperactivity disorder, comorbid oppositional defiant disorder, 111:181 depressive disorder, effect of subthreshold stimulation course of transcranial magnetic stimulation, 113:245

Subject Index oppositional defiant disorder comorbid with attention deficit hyperactivity disorder, 111:181 quantitative EEG analysis, adult patients with attention deficit hyperactivity disorder, 112:133 transcranial magnetic stimulation, effect of subthreshold stimulation course in depressive disorder, 113:245 Emotion alcoholism, attention direction, facial affect perception, 113:161 anxiety, memory for facial expressions in depression, 113:279 depressive disorder, memory for facial expressions, 113:279 face and affect-recognition tasks, social functioning, schizophrenia, 112:41 facial affect perception, alcoholism, attention direction, 113:161 memory for facial expressions, depressive disorder, 113:279 schizophrenia, face and affect-recognition tasks, social functioning, 112:41 Epidemiology alcoholism, association with traumatic brain injury, Northern Finland Birth Cohort Study, 113:217 criminality, association with traumatic brain injury, Northern Finland Birth Cohort Study, 113:217 mental disorders, association with traumatic brain injury, Northern Finland Birth Cohort Study, 113:217 mental disorders, traumatic brain injury, 113:217 panic attack, early-onset fearful panic as predictor of psychopathology, Epidemiologic Catchment Area Survey, 109:71 personality, Revised NEO Personality Inventory and Temperament and Character Inventory, Hopkins Epidemiology of Personality Study, 111:55 Parental Bonding Instrument, child rearing, influence on personality traits, Hopkins Epidemiology of Personality Study, 111:55 personality traits, influence of child rearing, Hopkins Epidemiology of Personality Study, 111:55 personality traits, Parental Bonding Instrument, effects of parenting style, 111:55 psychopathology, early-onset fearful panic as predictor, Epidemiologic Catchment Area Survey, 109:71 Revised NEO Personality Inventory, child rearing, effects on normal personality traits, Hopkins Epidemiology of Personality Study, 111:55 Temperament and Character Inventory, effects of parenting normal personality traits, Hopkins Epidemiology of Personality Study, 111:55 traumatic brain injury, association with alcoholism, criminality, mental disorders, Northern Finland Birth Cohort Study, 113:217 Epinephrine depressive disorder, stimulation of GTPase activity in platelet membranes, 112:111

325

GTPase activity in platelet membranes, guanine nucleotidebinding regulatory proteins, schizophrenia, depressive disorder, 112:111 guanine nucleotide-binding regulatory proteins, GTPase activity in platelet membranes in response to epinephrine stimulation, schizophrenia, depressive disorder, 112:111 schizophrenia, stimulation of GTPase activity in platelet membranes, 112:111

Ethnicity age, measurement adequacy of Center for Epidemiologic Studies-Depression Scale in elderly African-Americans, 109:61 Beck Depression Inventory-II, correlation with Center for Epidemiologic Studies-Depression Scale in Japanese sample, 110:291 Beck Depression Inventory-II, factor analysis and cross-cultural validation in Japanese sample, 110:291 Center for Epidemiologic Studies-Depression Scale, correlation with Beck Depression Inventory-II in Japanese sample, 110:291 Center for Epidemiologic Studies-Depression Scale, differential item functioning analysis in African-American, Hispanic and non-Hispanic white community-dwelling young adults, 110:281 Center for Epidemiologic Studies-Depression Scale, factor analysis and measurement adequacy in sample of elderly African-Americans, 109:61 Center for Epidemiologic Studies-Depression Scale, depressive symptoms, 110:281 depressive symptoms, cross-cultural validation of Beck Depression Inventory-II in Japanese sample, 110:291 depressive symptoms, differential item functioning analysis, in African-American, Hispanic and non-Hispanic white community-dwelling young adults, 110:281

Ethology depressive disorder, nonverbal interaction involvement, observational ratings of patient-interviewer dyads, outcome prediction, 113:269 nonverbal interaction involvement, observational ratings of patient-interviewer dyads, outcome prediction in depressive disorder, 113:269

Evoked potentials auditory oddball task, numbing symptoms, posttraumatic stress disorder, 109:171 error-related negativity, obsessive-compulsive characteristics in college students, Stroop task, 110:63 N2 and P3 components, schizophrenia, 111:167 obsessive-compulsive characteristics in college students, Stroop task, 110:63 posttraumatic stress disorder, auditory oddball task, numbing symptoms, 109:171

326

Subject Index

schizophrenia, N2 and P3 components, 111:167 Stroop task, error-related negativity, obsessive-compulsive characteristics in college students, 110:63 Expressed emotion age of schizophrenic patient, communication patterns, Family Problem-Solving Task, 109:161 Camberwell Family Interview validation of Family Interview in families of schizophrenic patients, 109:265 communication patterns, Family Problem-Solving Task in families of schizophrenic patients, Relational Control Coding System, 109:161 depressive disorder, disorder severity in first episodes, 111:155 depressive disorder, Five-Minute Speech Sample, 111:155, 112:239, 112:231 depressive disorder, validity of Five-Minute Speech Sample in Japanese sample, 112:231 Family Attitude Scale, Relational Control Coding System, communication in families of schizophrenic patients, 110:273 Family Questionnaire, validation by Camberwell Family Interview, schizophrenia, 109:265 Five-Minute Speech Sample, depressive disorder, 111:155, 112:239, 112:231 Five-Minute Speech Sample, disorder severity in first episodes of depression and schizophrenia, 111:155 Five-Minute Speech Sample, schizophrenia, 109:161, 111:155, 112:239 Five-Minute Speech Sample, validity in Japanese sample, 112:231 schizophrenia, age of patient, communication patterns, Family Problem-Solving Task, 109:161 schizophrenia, Camberwell Family Interview validation of Family Questionnaire, 109:265 schizophrenia, disorder severity in first episodes, 111:155 schizophrenia, Family Attitude Scale, 110:273 schizophrenia, Family Problem-Solving Task, 109:161 schizophrenia, Family Questionnaire, 109:265 schizophrenia, Five-Minute Speech Sample, 109:161, 111:155, 112:239 Eye movements catechol-O-methyltransferase gene, schizophrenia, fixation and smooth-pursuit tests, 113:49 fixation and smooth-pursuit tests, catechol-O-methyltransferase gene, schizophrenia, 113:49 genetics, catechol-O-methyltransferase gene, fixation and smooth-pursuit tests, schizophrenia, 113:49 schizophrenia, catechol-O-methyltransferase gene, fixation and smooth-pursuit tests, 113:49 Family Attitude Scale expressed emotion, measurement of criticism in the relatives of patients with schizophrenia in Japan, 110:273 schizophrenia, expressed emotion, measurement of criticism in the relatives of patients in Japan, 110:273

Family environment anticipatory stress response, salivary cortisol responses in sons and daughters of drug abusers, 112:121 cortisol measured in saliva, anticipatory stress response, in sons and daughters of drug abusers, 112:121 drug dependence, salivary cortisol in sons and daughters of drug abusers, anticipatory stress response, 112:121 sex differences, anticipatory stress response, salivary cortisol in sons and daughters of drug abusers, 112:121 stress, salivary cortisol response in sons and daughters of drug abusers, 112:121 Family Questionnaire Camberwell Family Interview validation, expressed emotion, family members of schizophrenic patients, 109:265 schizophrenia, Camberwell Family Interview validation of brief self-report questionnaire as measure of expressed emotion in family members of schizophrenic patients, 109:265 Fenfluramine depressive disorder, prolactin response, measures of personality and temperament, 109:221 Eysenck Personality Questionnaire, prolactin responses in depressed men, 109:221 olanzapine, prolactin response in schizophrenia, 113:41 personality, Eysenck Personality Questionnaire, 109:221 personality, prolactin response in depressed men, 109:221 prolactin, olanzapine, schizophrenia, 113:41 prolactin, response in depressed men, 109:221 schizophrenia, olanzapine, prolactin response, 113:41 Tridimensional Personality Questionnaire, prolactin response in depressed men, 109:221 Fluoxetine clinical response predictors in depressive disorder, NEO FiveFactor Personality Inventory, neuroticism score, 109:9 depressive disorder, clinical response predictors, NEO FiveFactor Personality Inventory, neuroticism score, 109:9 NEO Five-Factor Personality Inventory, neuroticism score, clinical response predictors, depressive disorder, 109:9 Fluvoxamine antidepressant response, depressive disorder, serotonin transporter gene, 111:235 clonidine REM suppression test, alpha-2 adrenergic receptors, clonidine REM suppression test, depressive disorder, 109:1 depressive disorder, antidepressant response, serotonin transporter gene, 111:235 depressive disorder, clonidine REM suppression test, 109:1 genetics, antidepressant response, 111:235 genetics, depressive disorder, serotonin transporter gene, 111:235 serotonin transporter gene, antidepressant response, 111:235 sleep, clonidine REM suppression test, depressive disorder, 109:1

Subject Index Frontal Systems Behavior Scale apathy and disinhibition, cognition, executive function, schizophrenia, 113:227 executive function, apathy and disinhibition, schizophrenia, 113:227 schizophrenia, apathy and disinhibition, cognition, executive function, social functioning and symptomatology, 113:227 Frontotemporal lobar degeneration dementia, Stereotypy Rating Inventory, 110:175 Stereotypy Rating Inventory, dementia, 110:175 Genetics alcoholism, monoamine oxidase A promoter polymorphism, 109:113 alcoholism, norepinephrine transporter gene polymorphism, 111:229 anticipation of age at onset, obsessive-compulsive spectrum disorders, 111:1 antidepressant response, depressive disorder, fluvoxamine, serotonin transporter gene, 111:235 catechol-O-methyltransferase gene, eye movements, fixation and smooth-pursuit tests, schizophrenia, 113:49 circadian rhythm, Clock gene, delayed sleep phase syndrome, non-24-hour sleep-wake syndrome, 109:121 Clock gene, delayed sleep phase syndrome, non-24-hour sleep-wake syndrome, 109:121 cocaine, African-American cocaine-dependent sample, impulsivity and aggression, serotonin transporter polymorphisms, 110:103 CTLA-4 gene polymorphism, schizophrenia, Korean sample, 110:19 depressive disorder, antidepressant response, fluvoxamine, serotonin transporter gene, 111:235 eye movements, fixation and smooth-pursuit tests, catecholO-methyltransferase gene, schizophrenia, 113:49 fluvoxamine, antidepressant response, serotonin transporter gene, 111:235 GluR6 kainate receptor gene in Japanese sample, glutamatergic dysfunction hypothesis, schizophrenia, 113:59 impulsivity and aggression, African-American cocaine-dependent sample, serotonin transporter polymorphisms, 110:103 monoamine oxidase A promoter polymorphism, Finnish male alcoholics, 109:113 norepinephrine transporter gene polymorphism, alcoholism, 111:229 obsessive-compulsive disorder, anticipation of age at onset, 111:1 obsessive-compulsive spectrum disorders, anticipation of age at onset, 111:1 personality, impulsivity and aggression, African-American cocaine-dependent sample, serotonin transporter polymorphisms, 110:103 platelet-activating factor-acetylhydrolase, Val279Phe mutation, schizophrenia, Japanese population, 109:93 schizophrenia, catechol-O-methyltransferase gene, eye movements, fixation and smooth-pursuit tests, 113:49

327

schizophrenia, CTLA-4 gene polymorphism, Korean sample, 110:19 schizophrenia, GluR6 kainate receptor gene in Japanese sample, glutamatergic dysfunction hypothesis, 113:59 schizophrenia, serotonin, 5-HT6 receptor gene polymorphism, 110:97 schizophrenia, tardive dyskinesia, platelet-activating factoracetylhydrolase, Val279Phe mutation, 109:93 serotonin, African-American cocaine-dependent sample, impulsivity and aggression, serotonin transporter polymorphisms, 110:103 serotonin, 5-HT6 receptor gene polymorphism, schizophrenia, tardive dyskinesia, 110:97 serotonin transporter gene, antidepressant response, fluvoxamine, 111:235 serotonin transporter polymorphisms, African-American cocaine-dependent sample, impulsivity and aggression, 110:103 sleep, circadian rhythm, Clock gene, delayed sleep phase syndrome, non-24-hour sleep-wake syndrome, 109:121 tardive dyskinesia, serotonin, 5-HT6 receptor gene polymorphism, schizophrenia, 110:97 Val279Phe mutation, platelet-activating factor-acetylhydrolase, schizophrenia, 109:93 Glycogen synthase kinase-3 (GSK-3) schizophrenia, lymphocytes, 112:51 Guanine nucleotide-binding regulatory (G) proteins depressive disorder, epinephrine- and thrombin-stimulated GTPase activity in platelet membranes, 112:111 epinephrine-stimulated GTPase activity in platelet membranes, schizophrenia, depressive disorder, 112:111 GTPase activity in platelet membranes, epinephrine and thrombin stimulation, schizophrenia, depressive disorder, 112:111 schizophrenia, epinephrine- and thrombin-stimulated GTPase activity in platelet membranes, 112:111 thrombin-stimulated GTPase activity in platelet membranes, depressive disorder, schizophrenia, 112:111 Hallucinations auditory masking, acoustic hallucinations, psychoacoustics, schizophrenia, 113:115 psychoacoustics, acoustic hallucinations, auditory masking, schizophrenia, 113:115 schizophrenia, acoustic hallucinations, auditory masking, psychoacoustics, 113:115 Haloperidol clomipramine, prolactin response to clomipramine vs. haloperidol, duration of illness, Positive and Negative Syndrome Scale, schizophrenia, 110:9 olanzapine, sex differences in clinical response vs. haloperidol, schizophrenia, 110:27

328

Subject Index

polysomnography, risperidone vs. haloperidol effects on sleep, slow-wave sleep, schizophrenia, 109:137 Positive and Negative Syndrome Scale, prolactin response to clomipramine vs. haloperidol, schizophrenia, 110:9 prolactin response to clomipramine vs. haloperidol, schizophrenia, 110:9 risperidone vs. haloperidol, polysomnography, schizophrenia, slow-wave sleep, 109:137 schizophrenia, polysomnography, risperidone vs. haloperidol, slow-wave sleep, 109:137 schizophrenia, prolactin response to clomipramine vs. haloperidol, 110:9 schizophrenia, sex differences in response to olanzapine vs. haloperidol, 110:27 sleep, polysomnography, risperidone vs. haloperidol, schizophrenia, 109:137 Heart rate anxiety, isoproterenol, lactate, largest Lyapunov exponents, time-series analysis, 109:81 depressive disorder, severity of symptoms and modulation of cardiovagal response, 113:139 isoproterenol, anxiety, lactate, largest Lyapunov exponents, time-series analysis, 109:81 lactate, anxiety, isoproterenol, 109:81 lactate, largest Lyapunov exponents, time-series analysis, 109:81 Hippocampus clozapine, hippocampal HT22 cells, schizophrenia, 112:221 hippocampal HT22 cells, clozapine, schizophrenia, 112:221 schizophrenia, clozapine, 112:221 schizophrenia, hippocampal HT22 cells, serotonin, clozapine, 112:221 Hypocretin-1 orexins in cerebrospinal fluid, sleep architecture, schizophrenia, 110:1 schizophrenia, orexins in cerebrospinal fluid, sleep architecture, 110:1 sleep, orexins in cerebrospinal fluid, 110:1 sleep, schizophrenia, orexins in cerebrospinal fluid, 110:1 Immune function cortisol, dexamethasone, depressive disorder, lymphocyte distribution and expression of adhesion molecules, 113:1 depressive disorder, cortisol, dexamethasone, lymphocyte distribution and expression of adhesion molecules, 113:1 dexamethasone, cortisol, depressive disorder, lymphocyte distribution and expression of adhesion molecules, 113:1 interleukin-6, obsessive-compulsive disorder, trichotillomania, 112:257 lymphocyte distribution and expression of adhesion molecules, cortisol, dexamethasone, depressive disorder, 113:1 obsessive-compulsive disorder, interleukin-6, 112:257 trichotillomania, interleukin-6, 112:257

Insomnia cortisol, melatonin, nocturnal endocrine measures in primary insomnia, polysomnography, 113:17 melatonin, nocturnal endocrine measures in primary insomnia, polysomnography, 113:17 polysomnography, nocturnal endocrine measures in primary insomnia, 113:17 polysomnography, sleep continuity, tryptophan depletion test, 109:129 REM sleep, tryptophan depletion test, 109:129 sleep, behavioral and emotional problems, Chinese adolescents, Youth Self-Report of Child Behavior Checklist, 111:75 sleep continuity, polysomnography, REM sleep, tryptophan depletion test, 109:129 tryptophan depletion test, polysomnography, 109:129

Interleukin-6 obsessive-compulsive disorder, trichotillomania, cerebrospinal fluid, 112:257

Ipsapirone anxiety, cortisol, prolactin, meta-chlorophenylpiperazine, depressive disorder, 113:29 cortisol, anxiety, depressive disorder, meta-chlorophenylpiperazine, 113:29 depressive disorder, anxiety, cortisol, prolactin, meta-chlorophenylpiperazine, 113:29 meta-chlorophenylpiperazine, anxiety, cortisol, prolactin, depressive disorder, 113:29 prolactin, anxiety, depressive disorder, meta-chlorophenylpiperazine, 113:29

Isoproterenol anxiety, heart rate, lactate, largest Lyapunov exponents, timeseries analysis, 109:81 heart rate, anxiety, lactate, largest Lyapunov exponents, timeseries analysis, 109:81

Lactate adrenocorticotropic hormone, panic attacks, 109:201 anxiety, heart rate, isoproterenol, largest Lyapunov exponents, time-series analysis, 109:81 heart rate, anxiety, isoproterenol, largest Lyapunov exponents, time-series analysis, 109:81 isoproterenol, anxiety, heart rate, largest Lyapunov exponents, time-series analysis, 109:81 panic attacks, adrenocorticotropic hormone, prolactin, 109:201 prolactin, panic attacks, 109:201

Language oral vs. written language, schizophrenia, 111:137 schizophrenia, oral vs. written language, 111:137

Subject Index Laterality attention, dichotic listening, schizophrenia, 109:281 Brodmann areas and brain hemispheres, imipramine and paroxetine binding, postsynaptic 5-HT2A binding sites, serotonin, 111:105 dichotic listening, attention, schizophrenia, 109:281 imipramine and paroxetine binding, Brodmann areas and brain hemispheres, postsynaptic 5-HT2A binding sites, 111:105 neuropathology, Brodmann areas and brain hemispheres, imipramine and paroxetine binding, postsynaptic 5-HT2A binding sites, 111:105 schizophrenia, dichotic listening, 109:281 serotonin, Brodmann areas and brain hemispheres, imipramine and paroxetine binding, postsynaptic 5-HT2A binding sites, 111:105 Leptin arginine vasopressin, depressive disorder, sexual diergism in plasma leptin measures, 113:255 depressive disorder, arginine vasopressin, sexual diergism in plasma leptin measures, 113:255 sexual diergism in plasma leptin measures, arginine vasopressin, depressive disorder, 113:255 Life Functioning Questionnaire bipolar affective disorder, self-report, role function in domains of work place, duties at home, leisure time with family and friends, 112:161 Lithium bipolar affective disorder, cross-national, seasonality of lithium plasma levels in Italy vs. Netherlands, 111:43 bipolar affective disorder, lithium plasma levels, seasonality, 111:35, 111:43 combined lithium plus clomipramine treatment, serotonin, interaction of lithium with 5-HT1B receptors, 111:117 depressive disorder, combined lithium plus clomipramine treatment, interaction of lithium with 5-HT1B receptors, 111:117 lithium plasma levels, bipolar affective disorder, seasonality, 111:35, 111:43 lithium plasma levels, seasonality in Italy vs. The Netherlands, 111:43 seasonality, lithium plasma levels, 111:3, 111:43 Magical ideation olfactory experiences, cross-cultural, German and Japanese healthy subjects, schizotypy, 111:21 schizotypy, cross-cultural, German and Japanese healthy subjects, olfactory experiences, 111:21 Major depression. See Depression Marijuana Chapman Psychosis Proneness Scales, schizotypy, 109:27

329

personality, Chapman Psychosis Proneness Scales, schizotypy, 109:27 schizotypy, Chapman Psychosis Proneness Scales, 109:27 Melatonin cortisol, insomnia, nocturnal endocrine measures in primary insomnia, polysomnography, 113:17 insomnia, cortisol, nocturnal endocrine measures in primary insomnia, polysomnography, 113:17 polysomnography, cortisol, insomnia, nocturnal endocrine measures in primary insomnia, 113:17 sleep, cortisol, insomnia, nocturnal endocrine measures in primary insomnia, polysomnography, 113:17 Memory anxiety, memory for facial expressions, 113:279 California Verbal Learning Test, memory-impaired subtype, schizophrenia, Sickness Impact Profile, 113:93 California Verbal Learning Test, schizophrenia, quality of life and positive symptoms, 113:93 depressive disorder, anxiety, memory for facial expressions, 113:279 mirror reading task, Japanese katakana characters in mirror image, procedural memory, schizophrenia, 109:303 phonological similarity effect, schizophrenia, short-term memory serial recall, 112:77 positive and negative symptoms, schizophrenia, source monitoring, 112:27 Positive and Negative Syndrome Scale, symptom clusters, working memory, schizophrenia, 110:49 procedural memory, Japanese katakana characters in mirror image, 109:303 procedural memory, mirror reading task, 109:303 procedural memory, schizophrenia, 109:303 quality of life and positive symptoms, memory-impaired subtype of schizophrenia, 113:93 schizophrenia, disorganized symptoms, 113:83 schizophrenia, Japanese katakana characters in mirror image, 109:303 schizophrenia, memory-impaired subtype, 113:93 schizophrenia, mirror reading task, 109:303 schizophrenia, phonological similarity effect, 112:77 schizophrenia, positive and negative symptoms, 112:27 schizophrenia, Positive and Negative Syndrome Scale, 110:49 schizophrenia, procedural memory, 109:303 schizophrenia, quality of life and positive symptoms, 113:93 schizophrenia, self-ordered pointing task, 110:259 schizophrenia, short-term memory serial recall, 112:77 schizophrenia, Sickness Impact Profile, 113:93 schizophrenia, source monitoring, 112:27 schizophrenia, spatial working memory span, 110:259 schizophrenia, symptom clusters, 110:49 schizophrenia, working memory, 110:49, 113:83 short-term memory serial recall, phonological similarity effect, schizophrenia, 112:77 Sickness Impact Profile, memory-impaired subtype of schizophrenia, 113:93

330

Subject Index

source monitoring, positive and negative symptoms, schizophrenia, 112:27 spatial working memory span, schizophrenia, 110:259 spatial working memory span, self-ordered pointing task, schizophrenia, 110:259 working memory and executive function, disorganized symptoms, schizophrenia, 113:83 working memory, Positive and Negative Syndrome Scale, schizophrenia, 110:49 Mental disorders epidemiology, Northern Finland Birth Cohort Study, traumatic brain injury, 113:217 traumatic brain injury, epidemiology, Northern Finland Birth Cohort Study, 113:217 Meta-chlorophenylpiperazine anxiety, cortisol, prolactin, depressive disorder, 113:29 cortisol, anxiety, depressive disorder, 113:29 depressive disorder, anxiety, cortisol, prolactin, 113:29 prolactin, anxiety, depressive disorder, serotonin, 113:29 Methamphetamine cognition, Stroop test, 111:65 Stroop test, cognition, 111:65 Mirror reading task memory, Japanese katakana characters in mirror image, schizophrenia, 109:303 schizophrenia, Japanese katakana characters in mirror image, procedural memory, 109:303 Mirtazapine alpha-2 adrenergic receptors, depressive disorder, normalization of blunted response to clonidine REM suppression test, 109:1 clonidine REM suppression test, normalization of blunted response, depressive disorder, 109:1 depressive disorder, clonidine REM suppression test, 109:1 sleep, clonidine REM suppression test, depressive disorder, 109:1 Monoamine oxidase A promoter polymorphism alcoholism, Finnish males, 109:113 genetics, Finnish male alcoholics, 109:113 Myocardial infarction beta-thromboglobulin, depression in cardiac patients, 109:207 depression in cardiac patients, beta-thromboglobulin, platelet factor 4, 109:207 platelet factor 4, depression in cardiac patients, 109:207 NEO Five-Factor Inventory depressive disorder, clinical response predictors, fluoxetine, 109:9 fluoxetine, clinical response predictors, depressive disorder, 109:9

neuroticism, clinical response predictor, depressive disorder, fluoxetine, 109:9 Neurologic soft signs posttraumatic stress disorder, female nurse Vietnam veterams, 110:81 Neuropathology Brodmann areas and brain hemispheres, laterality, Brodmann areas and brain hemispheres, imipramine and paroxetine binding, postsynaptic 5-HT2A binding sites, 111:105 imipramine and paroxetine binding, laterality, postsynaptic 5-HT2A binding sites, Brodmann areas and brain hemispheres, 111:105 laterality, Brodmann areas and brain hemispheres, imipramine and paroxetine binding, laterality, postsynaptic 5-HT2A binding sites, 111:105 serotonin, Brodmann areas and brain hemispheres, imipramine and paroxetine binding, postsynaptic 5-HT2A binding sites, 111:105 Neuropsychology benzodiazepines, medication effects, obsessive-compulsive disorder, 109:255 obsessive-compulsive disorder, benzodiazepines, serotonin reuptake inhibitors, 109:255 serotonin reuptake inhibitors, medication effects, obsessivecompulsive disorder, 109:255 Neuroticism depressive disorder, fluoxetine, clinical response predictors, NEO Five-Factor Personality Inventory, 109:9 Eysenck Personality Questionnaire, family history of suicide, 110:87 fluoxetine, clinical response predictors, depressive disorder, NEO Five-Factor Personality Inventory, 109:9 NEO Five-Factor Personality Inventory, depressive disorder, fluoxetine, clinical response predictors, 109:9 suicide, family history, Eysenck Personality Questionnaire, 110:87 Neurotrophic factor brain-derived neurotrophic factor in serum, depressive disorder severity, 109:143 brain-derived neurotrophic factor in serum, schizophrenia, 110:249 depression severity, serum brain-derived neurotrophic factor, 109:143 schizophrenia, brain-derived neurotrophic factor in serum, 110:249 Nitric oxide acute stress disorder, military rescue workers in Taiwan after earthquake, 112:59

Subject Index Norepinephrine alcoholism, norepinephrine transporter gene polymorphism, 111:229 clonidine challenge, cortisol, panic disorder, posttraumatic stress disorder, 110:219 cortisol, clonidine challenge, panic disorder, posttraumatic stress disorder, 110:219 genetics, alcoholism, norepinephrine transporter gene polymorphism, 111:229 panic disorder, cortisol, clonidine challenge, 110:219 posttraumatic stress disorder, cortisol, clonidine challenge, 110:219 Normal volunteers healthy subject recruitment, telephone screens, 113:295 telephone screens, healthy subject recruitment, 113:295 Obsessive-compulsive disorder anticipation of age at onset, obsessive-compulsive spectrum disorders, 111:1 benzodiazepines, neuropsychology, 109:255 evoked potentials, error-related negativity, obsessive-compulsive characteristics in college students, Stroop task, 110:63 executive function, go-no go task, Stroop task, 110:165 executive function, neuropsychological tests, schizotypy, 110:151 factor analysis, Yale-Brown Obsessive-Compulsive Scale, 109:193 genetics, anticipation of age at onset, obsessive-compulsive spectrum disorders, 111:1 interleukin-6, cerebrospinal fluid, 112:257 neuropsychological tests, cognition, executive function, schizotypy, 110:151 neuropsychology, benzodiazepines, serotonin reuptake inhibitors, medication effects, 109:255 obsessive-compulsive characteristics in college students, error-related negativity, evoked potentials, Stroop task, 110:63 obsessive-compulsive spectrum disorders, genetics, anticipation of age at onset, 111:1 personality, neuropsychological tests, 110:151 schizotypy, executive function, neuropsychological tests, 110:151 serotonin reuptake inhibitors, medication effects, neuropsychology, 109:255 Stroop task, error-related negativity, evoked potentials, 110:63 Stroop task, executive function, go-no go task, obsessive-compulsive characteristics in college students, 110:165 Yale-Brown Obsessive-Compulsive Scale, factor analysis, 109:193 Olanzapine fenfluramine, prolactin, schizophrenia, 113:41 haloperidol, sex differences in clinical response to olanzapine vs. haloperidol, schizophrenia, 110:27 prolactin, fenfluramine, schizophrenia, 113:41 schizophrenia, fenfluramine, prolactin, 113:41

331

schizophrenia, sex differences in clinical response to olanzapine vs. haloperidol, 110:27 serotonin, fenfluramine, prolactin, schizophrenia, 113:41 sex differences in clinical response to olanzapine vs. haloperidol, schizophrenia, 110:27 Olfactory experiences magical ideation, olfactory sensitivity, schizotypy, German and Japanese healthy subjects, 111:21 olfactory sensitivity, magical ideation, schizotypy, German and Japanese healthy subjects, 111:21 schizotypy, olfactory sensitivity, magical ideation, German and Japanese healthy subjects, 111:21 Opioid dependence childhood-onset psychopathology, risk factor for drug abuse in adulthood, 109:245 Oppositional defiant disorder attention deficit hyperactivity disorder, comorbidity, electroencephalography, 111:181 electroencephalography, comorbidity, attention deficit hyperactivity disorder, 111:181 Overt Aggression Scale-Modified interrater reliability, training for use in multicenter study using live mock interviews, 112:153 Panic disorder adrenocorticotropic hormone, lactate, panic attacks, 109:201 agoraphobia, false-suffocation alarm theory, Read’s rebreathing technique, 113:181 asthma, increased incidence of panic and anxiety disorders, 110:73 carbon dioxide challenge, administration of l-5-hydroxytryptophan inhibits panic, 113:237 carbon dioxide challenge test, clonazepam, 112:269 cholecystokinin tetrapeptide, trait dissociation, 111:93 clonazepam, carbon dioxide challenge test, 112:269 clonidine challenge, cortisol, 3-methoxy-4-hydroxyphenylglycol responses, comparison between panic disorder and posttraumatic stress disorder, 110:219 cortisol, 3-methoxy-4-hydroxyphenylglycol responses to clonidine challenge, comparison between panic disorder and posttraumatic stress disorder, 110:219 early-onset fearful panic, predictors of psychopathology, Epidemiologic Catchment Area Survey, 109:71 Epidemiologic Catchment Area Survey, predictors of psychopathology, early-onset fearful panic, 109:71 false-suffocation alarm theory, Read’s rebreathing technique, 113:181 lactate, adrenocorticotropic hormone, prolactin, panic attacks, 109:201 norepinephrine, cortisol, 3-methoxy-4-hydroxyphenylglycol responses to clonidine challenge, comparison between panic disorder and posttraumatic stress disorder, 110:219

332

Subject Index

panic attacks, lactate, adrenocorticotropic hormone, prolactin, 109:201 predictors of psychopathology, early-onset fearful panic, Epidemiologic Catchment Area Survey, 109:71 prolactin, adrenocorticotropic hormone, lactate, 109:201 Read’s rebreathing technique, agoraphobia, false-suffocation alarm theory, 113:181 serotonin, carbon dioxide challenge, administration of l-5-hydroxytryptophan inhibits panic, 113:237 trait dissociation, cholecystokinin tetrapeptide, 111:93 Paroxetine amisulpride vs. paroxetine, dysthymic disorder, outcome and psychosocial function, 112:145 dysthymic disorder, amisulpride, vs. paroxetine, outcome and psychosocial function, 112:145 Personality aggression, interrater reliability of Overt Aggression ScaleModified, training using mock interviews, 112:153 antisocial personality disorder, rapists, child molesters, sexual offenders, testosterone, 110:239 cannabis, Chapman Psychosis Proneness Scales, schizotypy, 109:27 Chapman Psychosis Proneness Scales, cannabis, schizotypy, 109:27 child rearing, effects on personality and temperament, Revised NEO Personality Inventory, Temperament and Character Inventory, 111:55 China’s one-child policy, Chinese university students, Plutchik-van Praag Depression Inventory, ZuckermanKuhlman Personality Questionnaire, 109:37 cholesterol, novelty Seeking, Temperament and Character Inventory, psychiatric inpatients with and without suicide attempts, 112:83 cocaine, impulsivity and aggression, serotonin transporter polymorphisms, African-American cocaine-dependent sample, 110:103 depressive disorder, fenfluramine, prolactin, clinical response predictors, Tridimentional Personality Questionnaire, Eysenck Personality Questionnaire, 109:221 depressive disorder, fluoxetine, clinical response predictors, NEO Five-Factor Personality Inventory, neuroticism, 109:9 depressive disorder, outcome, personality changes with recovery, Temperament and Character Inventory, 109:17 epidemiology, Parental Bonding Instrument, parenting effects on personality traits, Revised NEO Personality Inventory, Temperament and Character Inventory, 111:55 executive function, obsessive-compulsive characteristics, schizotypy, 110:151 Eysenck Personality Questionnaire, depressive disorder, prolactin response to fenfluramine, 109:221 fenfluramine, prolactin, depressive disorder, Eysenck Personality Questionnaire, Tridimensional Personality Questionnaire, 109:221 fluoxetine, clinical response predictors in depression, NEO Five-Factor Personality Inventory, neuroticism, 109:9

genetics, impulsivity and aggression, African-American cocaine dependent sample, serotonin transporter polymorphisms, 110:103 impulsivity and aggression, African-American cocaine-dependent sample, serotonin transporter polymorphisms, 110:103 marijuana, Chapman Psychosis Proneness Scales, schizotypy, 109:27 NEO Five-Factor Personality Inventory, neuroticism, response to fluoxetine in depression, 109:9 neuropsychological tests, executive function, obsessive-compulsive characteristics, schizotypy, 110:151 neuroticism, NEO Five-Factor Personality Inventory, prediction of response to fluoxetine in depression, 109:9 novelty seeking, Temperament and Character Inventory, cholesterol, psychiatric inpatients with and without suicide attempts, 112:83 obsessive-compulsive characteristics, executive function, neuropsychological tests, 110:151 Overt Aggression Scale-Modified, interrater reliability, 112:153 Parental Bonding Instrument, child rearing effects on personality traits, Revised NEO Personality Inventory, Temperament and Character Inventory, 111:55 personality changes with recovery in depressive disorder, Temperament and Character Inventory, 109:17 Plutchik-van Praag Depression Inventory, China’s one-child policy, Chinese university students, 109:37 prolactin, fenfluramine, depressive disorder, Eysenck Personality Questionnaire, Tridimensional Personality Questionnaire, 109:221 Revised NEO Personality Inventory, child rearing effects on personality traits, 111:55 schizotypy, Chapman Psychosis Proneness Scales, cannabis, 109:27 schizotypy, neuropsychological tests, 110:151 serotonin transporter polymorphisms, impulsivity and aggression, African-American cocaine-dependent sample, 110:103 substance dependence, impulsivity and aggression, serotonin transporter polymorphisms, African-American cocaine dependent sample, 110:103 suicide, cholesterol, novelty seeking, Temperament and Character Inventory, psychiatric inpatients with and without suicide attempts, 112:83 Temperament and Character Inventory, child rearing effects on personality traits, 111:55 Temperament and Character Inventory, cholesterol, novelty seeking, psychiatric inpatients with and without suicide attempts, 112:83 Temperament and Character Inventory, personality changes with recovery in depression, 109:17 testosterone, antisocial personality, rapists and child molesters, sexual offenders, 110:239 Tridimensional Personality Questionnaire, prolactin, fenfluramine, depressive disorder, 109:221 Zuckerman-Kuhlman Personality Questionnaire, China’s one-child policy, Chinese university students, 109:37

Subject Index Platelet activating factor genetics, Japanese population, platelet-activating factoracetylhydrolase deficiency, Val279Phe mutation, schizophrenia, 109:93 schizophrenia, genetics, Japanese population, platelet-activating factor-acetylhydrolase deficiency, Val279Phe mutation, 109:93 Val279Phe mutation, schizophrenia, Japanese population, platelet-activating factor-acetylhydrolase deficiency, 109:93 Platelet factor 4 depression in cardiac patients, myocardial infarction, 109:207 myocardial infarction, depression in cardiac patients, 109:207 Positive and Negative Syndrome Scale clomipramine, prolactin response, schizophrenia, haloperidol treatment, duration of illness, negative symptoms, general psychopathology scores, 110:9 haloperidol, prolactin response, schizophrenia, duration of illness, negative symptoms, general psychopathology scores, 110:9 memory, schizophrenia, negative, positive and disorganized symptom clusters, 110:49 prolactin, clomipramine, haloperidol, schizophrenia, duration of illness, negative symptoms, general psychopathology scores, 110:9 schizophrenia, clomipramine, haloperidol, duration of illness, negative symptoms, general psychopathology scores, 110:9 schizophrenia, negative, positive and disorganized symptom clusters, working memory, 110:49 working memory, schizophrenia, negative, positive and disorganized symptom clusters, 110:49 Postpartum depression Beck Depression Inventory, cholesterol, sample of healthy primaparous women, 109:213 cholesterol, Beck Depression Inventory, sample of healthy primaparous women, 109:213 depressive symptoms, Beck Depression Inventory, cholesterol, sample of healthy primaparous women, 109:213 Posttraumatic stress disorder (PTSD) auditory oddball task, evoked potentials, auditory oddball task, numbing symptoms, 109:171 clonidine challenge, comparison between panic disorder and PTSD, differences in cortisol and 3-methoxy-4-hydroxyphenylglycol responses to clonidine, 110:219 cognition, combat veterans, semantic processing of traumarelevant words, sentence completion test, 112:299 cognition, trauma survivors, impaired attention, poor recall for figural information, lower IQ, associated with more PTSD symptoms, 110:231 cortisol and 3-methoxy-4-hydroxyphenylglycol response to clonidine challenge, comparison between panic disorder and PTSD patients, 110:219 disaster-related outcomes and interventions, literature review of post-disaster interventions, 110:201

333

evoked potentials, auditory oddball task, numbing symptoms, 109:171 military service, Israeli Draft Board screening tests, motivation to serve, vulnerability to PTSD, 109:45 neurologic soft signs, female nurse Vietnam veterans, 110:81 norepinephrine, clonidine challenge, cortisol, comparison between panic disorder and PTSD patients, 110:219 numbing symptoms, auditory oddball task, 109:171 numbing symptoms, evoked potentials, 109:171 semantic processing of trauma-relevant words, combat veterans, 113:303 sentence completion test, combat veterans, 113:303 trauma survivors, impaired attention, poor recall for figural information, lower IQ, associated with more PTSD symptoms, 110:231 visuospatial copying tasks, impairment associated with chronic PTSD in groups of trauma-exposed subjects, 112:263 vulnerability to PTSD, Israeli Draft Board screening tests, motivation to serve in military, 109:45 Prolactin antipsychotic medication effects, schizophrenia, menstrual dysfunction, ovarian hormone values, 111:11 anxiety, depressive disorder, response to ipsapirone vs. metachlorophenylpiperazine, 113:29 clomipramine, haloperidol, Positive and Negative Syndrome Scale, schizophrenia, 110:9 depressive disorder, anxiety, response to ipsapirone vs. metachlorophenylpiperazine, 113:29 depressive disorder, personality characteristics, Eysenck Personality Questionnaire, Tridimensional Personality Questionnaire, response to fenfluramine, 109:221 dopamine D2 receptor agonist, quinagolide, social phobia, 111:87 fenfluramine, olanzapine, schizophrenia, 113:41 fenfluramine, personality characteristics related to response to serotonin challenge, depressive disorder, 109:221 haloperidol, schizophrenia, duration of illness, Positive and Negative Syndrome Scale, 110:9 ipsapirone, response to challenge in depressive disorder, 113:29 lactate, panic attacks, 109:201 menstrual dysfunction, ovarian hormone values, antipsychotic medication effects, schizophrenia, 111:11 meta-chlorophenylpiperazine, response to serotonin challenge in depressive disorder, 113:29 olanzapine, fenfluramine, schizophrenia, 113:41 panic attacks, lactate, 109:201 quinagolide, dopamine D2 receptor agonist, social phobia, 111:87 risperidone, positive symptom improvement, schizophrenia, 109:297 schizophrenia, duration of illness, clomipramine, haloperidol, Positive and Negative Syndrome Scale, 110:9 schizophrenia, fenfluramine, olanzapine, 113:41 schizophrenia, haloperidol, 110:9 schizophrenia, menstrual dysfunction, ovarian hormone values, antipsychotic medication effects, 111:11

334

Subject Index

schizophrenia, positive symptom improvement, risperidone, 109:297 schizophrenia, risperidone, 109:297 schizophrenia, serotonin, fenfluramine, 113:41 serotonin, ipsapirone, 113:29 serotonin, meta-chlorophenylpiperazine, depressive disorder, 113:29 serotonin, olanzapine, schizophrenia, 113:41 social phobia, dopamine D2 receptor agonist, quinagolide, 111:87 Psychoacoustics acoustic hallucinations, auditory masking, schizophrenia, 113:115 auditory masking, acoustic hallucinations, schizophrenia, 113:115 schizophrenia, acoustic hallucinations, auditory masking, 113:115 Psychomotor activity agitation and retardation, depression subtypes, more common in melancholia, 112:211 Quality of life cross-cultural, Japanese version of Schizophrenia Quality of Life Scale, reliability and validity, 113:107 Japanese version of Schizophrenia Quality of Life Scale, reliability and validity, 113:107 schizophrenia, cross-cultural, Japanese version of Schizophrenia Quality of Life Scale, reliability and validity, 113:107 Quinagolide dopamine D2 receptor agonist, prolactin, social phobia, 111:87 prolactin, dopamine D2 receptor agonist, social phobia, 111:87 social phobia, dopamine D2 receptor agonist, prolactin, 111:87 Repetitive transcranial magnetic stimulation. See Transcranial magnetic stimulation Risperidone haloperidol vs. risperidone, polysomnography, slow-wave sleep, schizophrenia, 109:137 polysomnography, haloperidol vs. risperidone, slow-wave sleep, schizophrenia, 109:137 prolactin, positive symptom improvement, schizophrenia, 109:297 schizophrenia, haloperidol vs. risperidone, polysomnography, slow-wave sleep, 109:137 schizophrenia, positive symptom improvement, prolactin response, 109:297 sleep, slow-wave, haloperidol vs. risperidone, schizophrenia, 109:137 Schizophrenia acoustic hallucinations, auditory masking, psychoacoustics, 113:115

age of patient, family communication patterns, Family Problem-Solving Task, expressed emotion, Five-Minute Speech Sample, 109:161 antipsychotic medication effects, menstrual dysfunction, ovarian hormone values, prolactin, 111:11 apathy and disinhibition, Frontal Systems Behavior Scale, 113:227 attention, dichotic listening, laterality, 109:281 auditory masking, acoustic hallucinations, psychoacoustics, 113:115 brain-derived neurotrophic factor in serum, 110:249 California Verbal Learning Test, memory-impaired subtype, 113:93 Camberwell Family Interview validation for Family Questionnaire, expressed emotion, 109:265 catechol-O-methyltransferase gene, eye movements, fixation and smooth-pursuit tests, 113:49 clomipramine, duration of illness, 110:9 clomipramine, haloperidol, 110:9 clomipramine, Positive and Negative Syndrome Scale, 110:9 clomipramine, prolactin, 110:9 clozapine, hippocampal HT22 cells, 112:221 communication patterns, Family Problem-Solving Task, Relational Control Coding System, 109:161 cross-cultural, Japanese version of Schizophrenia Quality of Life Scale, reliability and validity, 113:107 CTLA-4 gene polymorphism, Korean sample, 110:19 dichotic listening, laterality, 109:281 disorganized symptoms, working memory and executive function, 113:83 duration of illness, clomipramine, 110:9 duration of illness, haloperidol, 110:9 duration of illness, Positive and Negative Syndrome Scale, 110:9 duration of illness, prolactin, 110:9 dynamic symptom patterns and outcome, time series models of symptoms, 113:127 early intervention program in first episodes, changes in memory and executive function, 113:69 emotion, face and affect-recognition tasks, social functioning, Social Dysfunction Index, 112:41 epinephrine, GTPase activity in platelet membranes, guanine nucleotide-binding regulatory proteins, 112:111 evoked potentials, N2 and P3 components, 111:167 executive function, apathy and disinhibition, Frontal Systems Behavior Scale, 113:227 expressed emotion, age of patient, 109:161 expressed emotion, Camberwell Family Interview validation of Family Questionnaire, 109:265 expressed emotion, disorder severity in first episodes, 111:155 expressed emotion, Family Attitude Scale, 110:273 expressed emotion, family communication patterns, 109:161 expressed emotion, Family Questionnaire, 109:265 expressed emotion, Five-Minute Speech Sample, 109:161, 111:155, 112:239 eye movements, fixation and smooth-pursuit tests, catecholO-methyltransferase gene, 113:49

Subject Index face and affect-recognition tasks, Social Dysfunction Index, 112:41 Family Attitude Scale, expressed emotion, 110:273 Family Problem-Solving Task, communication patterns, Relational Control Coding System, 109:161 Family Questionnaire as measure of expressed emotion, validation with Camberwell Family Interview, 109:265 fenfluramine, olanzapine, prolactin, 113:41 first-episode psychosis, insight and attitudes toward treatment, medication compliance, 110:39 Five-Minute Speech Sample, expressed emotion, 109:161, 111:155, 112:239 fixation and smooth-pursuit eye-movement tests, catechol-Omethyltransferase gene, 113:49 Frontal Systems Behavior Scale, apathy and disinhibition, 113:227 Frontal Systems Behavior Scale, executive function, 113:227 Frontal Systems Behavior Scale, social functioning and symptomatology, 113:227 genetics, catechol-O-methyltransferase gene, eye movements, fixation and smooth-pursuit tests, 113:49 genetics, CTLA-4 gene polymorphism, Korean sample, 110:19 genetics, GluR6 kainate receptor gene in Japanese sample, glutamatergic dysfunction hypothesis, 113:59 genetics, platelet-activating factor-acetylhydrolase, Val279Phe mutation, Japanese population, 109:93 genetics, serotonin, 5-HT6 receptor gene polymorphism, tardive dyskinesia, 110:97 GluR6 kainate receptor gene in Japanese sample, glutamatergic dysfunction hypothesis, 113:59 glutamatergic dysfunction hypothesis, GluR6 kainate receptor gene in Japanese sample, 113:59 glycogen synthase kinase-3, lymphocytes, 112:51 GTPase activity in platelet membranes, guanine nucleotide-binding regulatory proteins, 112:111 GTPase activity in platelet membranes, thrombin and epinephrine stimulation, 112:111 guanine nucleotide-binding regulatory proteins, epinephrine, 112:111 guanine nucleotide-binding regulatory proteins, GTPase activity in platelet membranes, 112:111 guanine nucleotide-binding regulatory proteins, thrombin, 112:111 hallucinations, acoustic, auditory masking, 113:115 haloperidol, clomipramine, 110:9 haloperidol, duration of illness, 110:9 haloperidol, olanzapine, 110:27 haloperidol, polysomnography, 109:137 haloperidol, Positive and Negative Syndrome Scale, 110:9 haloperidol, prolactin, 110:9 haloperidol, risperidone, 109:137 haloperidol, sex differences in treatment response, 110:27 haloperidol, slow-wave sleep, 109:137 hippocampal HT22 cells, clozapine, 112:221 hypocretin-1, orexins in cerebrospinal fluid, sleep architecture, 110:1

335

insight and attitudes toward treatment, medication compliance in first-episode psychosis, 110:39 Kraepelinian subtype, negative symptoms, season of birth, 111:147 language, oral vs. written language, 111:137 laterality, attention, dichotic listening, 109:281 lymphocytes, glycogen synthase kinase-3, 112:51 medication compliance, first-episode psychosis, insight and attitudes toward treatment, 110:39 memory, disorganized symptoms, 113:83 memory-impaired subtype, California Verbal Learning Test, 113:93 memory-impaired subtype, quality of life and positive symptoms, 113:93 memory-impaired subtype, Sickness Impact Profile, 113:93 memory, mirror reading task, 109:303 memory, phonological similarity effect, 112:77 memory, positive and negative symptoms, 112:27 memory, Positive and Negative Syndrome Scale, 110:49 memory, procedural memory, 109:303 memory, quality of life and positive symptoms, 113:93 memory, self-ordered pointing task, 110:259 memory, short-term memory serial recall, 112:77 memory, Sickness Impact Profile, 113:93 memory, source monitoring, 112:27 memory, spatial working memory span, 110:259 memory, symptom clusters, 110:49 memory, working, 110:49, 113:83 menstrual dysfunction, ovarian hormone values, prolactin, antipsychotic medication effects, 111:11 mirror reading task, procedural memory, Japanese katakana characters in mirror image, 109:303 motion perception and working memory, visual psychophysical tests and neuropsychological, 111:125 negative symptoms, Kraepelinian subtype, season of birth, 111:147 neurotrophic factor, brain-derived, in serum, 110:249 olanzapine, haloperidol, 110:27 olanzapine, prolactin response to fenfluramine, 113:41 olanzapine, sex differences in treatment response, 110:27 oral vs. written language, 111:137 orexins in cerebrospinal fluid, sleep architecture, 110:1 ovarian hormone values, antipsychotic medication effects, prolactin, 111:11 perceptual organization, Stroop task, top-down processing, 110:125 phonological similarity effect, short-term memory serial recall, 112:77 platelet-activating factor-acetylhydrolase, Val279Phe mutation, Japanese population, 109:93 polysomnography, haloperidol vs. risperidone, slow-wave sleep, 109:137 positive and negative symptoms, source monitoring, 112:27 Positive and Negative Syndrome Scale, clomipramine, 110:9 Positive and Negative Syndrome Scale, haloperidol, 110:9 Positive and Negative Syndrome Scale, positive symptom improvement, 109:297

336

Subject Index

Positive and Negative Syndrome Scale, prolactin, 109:297, 110:9 Positive and Negative Syndrome Scale, psychomotor poverty subsyndrome, 112:13 Positive and Negative Syndrome Scale, risperidone, 109:297 Positive and Negative Syndrome Scale, symptom clusters, 110:49 procedural memory, Japanese katakana characters in mirror image, mirror reading task, 109:303 prolactin, antipsychotic medication effects, 111:11 prolactin, clomipramine, 110:9 prolactin, duration of illness, 110:9 prolactin, fenfluramine, 113:41 prolactin, haloperidol, 110:9 prolactin, menstrual dysfunction, ovarian hormone values, 111:11 prolactin, olanzapine, 113:41 prolactin, Positive and Negative Syndrome Scale, 109:297, 110:9 prolactin, risperidone, 109:297 psychoacoustics, acoustic hallucinations, auditory masking, 113:115 psychomotor poverty subsyndrome, Positive and Negative Syndrome Scale, 112:13 quality of life and positive symptoms, memory-impaired subtype, Sickness Impact Profile, 113:93 quality of life, cross-cultural, Japanese version of Schizophrenia Quality of Life Scale, reliability and validity, 113:107 risperidone, positive symptom improvement, Positive and Negative Syndrome Scale, 109:297 risperidone, prolactin, 109:297 risperidone vs. haloperidol, polysomnography, slow-wave sleep, 109:137 season of birth, Kraepelinian subtype, negative symptoms, 111:147 self-ordered pointing task, spatial working memory span, 110:259 serotonin, clozapine, 112:221 serotonin, fenfluramine, 113:41 serotonin, hippocampal HT22 cells, 112:221 serotonin, olanzapine, 113:41 serotonin, prolactin, 113:41 serotonin, 5-HT6 receptor gene polymorphism, 110:97 serotonin, tardive dyskinesia, 110:97 sex differences in treatment response, haloperidol vs. olanzapine, 110:27 short-term memory serial recall, phonological similarity effect, 112:77 Sickness Impact Profile, memory-impaired subtype, quality of life and positive symptoms, 113:93 sleep architecture, hypocretin-1, 110:1 sleep architecture, orexins in cerebrospinal fluid, 110:1 sleep, haloperidol vs. risperidone, 109:137 sleep, hypocretin-1, 110:1 sleep latency, hypocretin-1, 110:1 sleep latency, orexins in cerebrospinal fluid, 110:1 sleep, orexins in cerebrospinal fluid, 110:1

sleep, polysomnography, 109:137 slow-wave sleep, haloperidol vs. risperidone, 109:137 slow-wave sleep, polysomnography, 109:137 social context processing, social perception, ward behavior, 109:149 Social Dysfunction Index, face and affect-recognition tasks, 112:41 social functioning and educational level, cognitively normal vs. cognitively impaired subgroup, 112:1 social functioning and symptomatology, Frontal Systems Behavior Scale, 113:227 social functioning, face and affect-recognition tasks, 112:41 social functioning, Social Dysfunction Index, 112:41 social perception, social context processing, ward behavior, 109:149 source monitoring, positive and negative symptoms, 112:27 spatial working memory span, self-ordered pointing task, 110:259 Stroop task, cognition, 110:125, 110:137 Stroop task, perceptual organization, top-down processing, 110:125 symptom clusters, Positive and Negative Syndrome Scale, 110:49 tardive dyskinesia, serotonin, 5-HT6 receptor gene polymorphism, 110:97 tasks requiring use of a rule, cognition, 109:289 thrombin, GTPase activity in platelet membranes, guanine nucleotide-binding regulatory proteins, 112:111 time series models of symptoms, dynamic symptom patterns and outcome, 113:127 Val279Phe mutation, platelet-activating factor-acetylhydrolase, Japanese population, 109:93 vision, motion perception and working memory, 111:125 vision, visual psychophysical tests and neuropsychological function, 111:125 ward behavior, social context processing, social perception, 109:149 Wisconsin Card Sorting Test perseveration, psychomotor poverty subsyndrome, 112:13 working memory and executive function, disorganized symptoms, 113:83 working memory, Positive and Negative Syndrome Scale, symptom clusters, 110:49 Schizotypy cannabis, Chapman Psychosis Proneness Scales, 109:27 Chapman Psychosis Proneness Scales, marijuana, 109:27 cognition, executive function, neuropsychological tests, 110:151 cross-cultural, German and Japanese healthy subjects, magical ideation, olfactory experiences, 111:21 executive function, neuropsychological tests, 110:151 magical ideation, German and Japanese healthy subjects, 111:21 magical ideation, olfactory experiences, 111:21 marijuana, Chapman Psychosis Proneness Scales, 109:27 neuropsychological tests, executive function, 110:151 olfactory experiences, German and Japanese healthy subjects, 111:21

Subject Index olfactory experiences, magical ideation, 111:21 Season of birth birth during peak flu season, depression and suicide, Southern vs. Northern Hemispheres, 112:89 depression, birth during peak flu season, Southern vs. Northern Hemispheres, 112:89 Kraepelinian subtype, negative symptoms, schizophrenia, 111:147 schizophrenia, Kraepelinian subtype, negative symptoms, 111:147 suicide, birth during peak flu season, Southern vs. Northern Hemispheres, 112:89 Seasonality atypical depression, outpatients, lack of seasonality in rates of presentation, 112:187 bipolar affective disorder, climate and sunlight variables, first manic episodes in Korea, 113:151 bipolar affective disorder, lithium plasma levels, cross-national, Italy vs. The Netherlands 111:43 bipolar affective disorder, lithium plasma levels, 111:35, 111:43 bulimia nervosa, outpatients, lack of seasonality in rates of presentation, 112:187 climate and sunlight variables, bipolar affective disorder, first manic episodes in Korea, 113:151 eating disorder, outpatients, lack of seasonality in rates of presentation, 112:187 lithium plasma levels, bipolar affective disorder, 111:35, 111:43 lithium plasma levels, Italy vs. The Netherlands, 111:43 suicidal ideation, outpatients, lack of seasonality in rates of presentation, 112:187 Serotonin administration of l-5-hydroxytryptophan inhibits panic, carbon dioxide challenge, 113:237 aggression and impulsivity, 5-hydroxyindoleacetic acid in cerebrospinal fluid, suicide, 113:193 antidepressant response, fluvoxamine, 5-HT6 receptor gene polymorphism, 111:235 anxiety, response to ipsapirone vs. meta-chlorophenylpiperazine, 113:29 Brodmann areas and brain hemispheres, laterality, imipramine and paroxetine binding, postsynaptic 5-HT2A binding sites, 111:105 carbon dioxide challenge, administration of l-5-hydroxytryptophan inhibits panic, 113:237 Childhood Trauma Questionnaire, self-rated childhood emotional neglect, cocaine abuse in adulthood, cerebrospinal fluid levels of 5-hydroxyindoleacetic acid, 112:69 clozapine, hippocampal HT22 cells, schizophrenia, 112:221 cocaine abuse, Childhood Trauma Questionnaire, self-rated childhood emotional neglect, cerebrospinal fluid levels of 5-hydroxyindoleacetic acid, 112:69 cocaine dependence, African-American sample, impulsivity and aggression, serotonin transporter polymorphisms, 110:103

337

cortisol response to ipsapirone and meta-chlorophenylpiperazine, depressive disorder, 113:29 depressive disorder, antidepressant response, fluvoxamine, 111:235 depressive disorder, combined lithium plus clomipramine treatment, 111:117 depressive disorder, cortisol and prolactin response to ipsapirone and meta-chlorophenylpiperazine, 113:29 depressive disorder, interaction of lithium with 5-HT1B receptors, 111:117 fenfluramine, prolactin response, olanzapine, schizophrenia, 113:41 fluvoxamine, antidepressant response, depressive disorder, 5HT6 receptor gene polymorphism, 111:235 genetics, antidepressant response, fluvoxamine, 5-HT6 receptor gene polymorphism, 111:235 genetics, serotonin transporter polymorphisms, impulsivity and aggression, African-American cocaine-dependent sample 110:103 genetics, tardive dyskinesia, schizophrenia, 110:97 hippocampal HT22 cells, clozapine, schizophrenia, 112:221 5-HT6 receptor gene polymorphism, tardive dyskinesia, schizophrenia, 110:97 5-hydroxyindoleacetic acid in cerebrospinal fluid, suicide, aggression and impulsivity, 113:193 imipramine and paroxetine binding, Brodmann areas and brain hemispheres, postsynaptic 5-HT2A binding sites, laterality, 111:105 impulsivity and aggression, serotonin receptor transporter polymorphism, African-American cocaine-dependent sample, 110:103 ipsapirone, anxiety, cortisol, and prolactin, depressive disorder, 113:29 laterality, Brodmann areas and brain hemispheres, imipramine and paroxetine binding, postsynaptic 5-HT2A binding sites, 111:105 lithium plus clomipramine treatment, interaction of lithium with 5-HT1B receptors, 111:117 meta-chlorophenylpiperazine, anxiety, cortisol and prolactin, depressive disorder, 113:29 neuropathology, Brodmann areas and brain hemispheres, imipramine and paroxetine binding, postsynaptic 5-HT2A binding sites, 111:105 olanzapine, fenfluramine, prolactin, schizophrenia, 113:41 panic disorder, administration of l-5-hydroxytryptophan inhibits panic attacks in response to carbon dioxide challenge, 113:237 prolactin, anxiety, ipsapirone vs. meta-chlorophenylpiperazine, depressive disorder, 113:29 prolactin, fenfluramine, olanzapine, schizophrenia, 113:41 schizophrenia, clozapine, hippocampal HT22 cells, 112:221 schizophrenia, fenfluramine, prolactin response, olanzapine, 113:41 schizophrenia, tardive dyskinesia, 5-HT6 receptor gene polymorphism, 110:97

338

Subject Index

serotonin transporter polymorphisms, impulsivity and aggression, African-American cocaine-dependent sample, 110:103 substance dependence, serotonin transporter polymorphisms, 110:103 suicidal behavior, cerebrospinal fluid levels of 5-hydroxyindoleacetic acid, 112:69 suicidal behavior, Childhood Trauma Questionnaire, self-rated childhood emotional neglect, 112:69 suicide, aggression and impulsivity, 113:193 suicide, 5-hydroxyindoleacetic acid in cerebrospinal fluid, 113:193 tardive dyskinesia, 5-HT6 receptor gene polymorphism, schizophrenia, 110:97 Sex anticipatory stress response, cortisol, salivary cortisol in sons and daughters of drug abusers, 112:121 arginine vasopressin, sexual diergism in plasma leptin measures, depressive disorder, 113:255 body shape preference, body image questionnaire in male vs. female Taiwanese college students, 111:215 cortisol in saliva, anticipatory stress response, in sons and daughters of drug abusers, 112:121 depressive disorder, arginine vasopressin, sexual diergism in plasma leptin measures, 113:255 haloperidol vs. olanzapine, schizophrenia, sex differences in treatment response, 110:27 leptin, arginine vasopressin, sexual diergism in plasma leptin measures, 113:255 olanzapine vs. haloperidol, schizophrenia, sex differences in treatment response, 110:27 schizophrenia, haloperidol vs. olanzapine, sex differences in treatment response, 110:27 stress, anticipatory response, salivary cortisol in sons and daughters of drug abusers, 112:121 Sexual offenders antisocial personality, rapists and child molesters, testosterone, 110:239 testosterone, antisocial personality, rapists and child molesters, 110:239 Sleep alpha-2 adrenergic receptors, clonidine REM suppression test, effects of fluvoxamine vs. mirtazapine, depressive disorder, 109:1 circadian rhythm, Clock gene, delayed sleep phase syndrome, non-24-hour sleep-wake syndrome, 109:121 Clock gene, delayed sleep phase syndrome, non-24-hour sleep-wake syndrome, 109:121 clonidine REM suppression test, alpha-2 adrenergic receptors, effects of fluvoxamine vs. mirtazapine, depressive disorder, 109:1 cortisol, nocturnal endocrine measures in primary insomnia, polysomnography, 113:17 delayed sleep phase syndrome, Clock gene, 109:121 depressive disorder, alpha-2 adrenergic receptors, clonidine

REM suppression test, effects of fluvoxamine vs. mirtazapine, 109:1 fluvoxamine, alpha-2 adrenergic receptors, clonidine REM suppression test, depressive disorder, 109:1 genetics, Clock gene, circadian rhythm, delayed sleep phase syndrome, non-24-hour sleep-wake syndrome, 109:121 haloperidol vs. risperidone, schizophrenia, polysomnography, slow-wave sleep, 109:137 hypocretin-1, cerebrospinal fluid, schizophrenia, sleep architecture, 110:1 insomnia, behavioral and emotional problems, Youth Self-Report of Child Behavior Checklist, Chinese adolescents, 111:75 insomnia, cortisol, melatonin, nocturnal endocrine measures in primary insomnia, polysomnography, 113:ER insomnia, REM sleep, sleep continuity, tryptophan depletion test, 109:129 melatonin, insomnia, nocturnal endocrine measures in primary insomnia, polysomnography, 113:17 mirtazapine, alpha-2 adrenergic receptors, clonidine REM suppression test, depressive disorder, 109:1 non-24-hour sleep-wake syndrome, Clock gene, 109:121 orexins in cerebrospinal fluid, sleep architecture, schizophrenia, 110:1 polysomnography, cortisol, nocturnal measures, insomnia, 113:17 polysomnography, haloperidol vs. risperidone, schizophrenia, slow-wave sleep, 109:137 polysomnography, insomnia, 109:129, 113:17 polysomnography, melatonin, nocturnal measures, insomnia, 113:17 polysomnography, nocturnal endocrine measures in primary insomnia, 113:17 polysomnography, REM sleep, 109:129 polysomnography, risperidone vs. haloperidol, schizophrenia, slow-wave sleep, 109:137 polysomnography, sleep continuity, 109:129 polysomnography, tryptophan depletion test, 109:129 REM sleep, insomnia, 109:129 REM sleep, sleep continuity, 109:129 REM sleep, tryptophan depletion test, 109:129 risperidone vs. haloperidol, polysomnography, schizophrenia, slow-wave sleep, 109:137 schizophrenia, haloperidol vs. risperidone, polysomnography, slow-wave sleep, 109:137 schizophrenia, hypocretin-1, cerebrospinal fluid, 110:1 schizophrenia, orexins in cerebrospinal fluid, 110:1 schizophrenia, polysomnography, 109:137 schizophrenia, risperidone vs. haloperidol, polysomnography, slow-wave sleep, 109:137 schizophrenia, sleep architecture, 110:1 schizophrenia, sleep latency, 110:1 schizophrenia, slow-wave sleep, 109:137 sleep architecture, hypocretin-1, orexins in cerebrospinal fluid, schizophrenia, 110:1 sleep continuity, insomnia, REM sleep, tryptophan depletion test, 109:129

Subject Index sleep duration, behavioral and emotional problems, Chinese adolescents with insomnia, 111:75 sleep latency, hypocretin-1, orexins in cerebrospinal fluid, schizophrenia, 110:1 slow-wave sleep, haloperidol vs. risperidone, schizophrenia, 109:137 tryptophan depletion test, insomnia, polysomnography, REM sleep, sleep continuity, 109:129 Social function face and affect-recognition tasks, schizophrenia, Social Dysfunction Index, 112:41 schizophrenia, face and affect-recognition tasks, Social Dysfunction Index, 112:41 Social perception schizophrenia, social context processing, ward behavior, 109:149 Social phobia dopamine D2 receptor agonist, quinagolide, prolactin response, 111:87 prolactin response to dopamine D2 receptor agonist, quinagolide, 111:87 quinagolide, dopamine D2 receptor agonist, prolactin response, 111:87 Stereotypy Rating Inventory frontotemporal lobar degeneration, dementia, 110:175 Stress. See also Posttraumatic stress disorder acute stress disorder, nitric oxide, rescue workers in Taiwan, 112:59 anticipatory stress response, salivary cortisol in sons and daughters of drug abusers, 112:121 cortisol, salivary levels in sons and daughters of drug abusers, anticipatory stress response, 112:121 nitric oxide, acute stress disorder, rescue workers in Taiwan, 112:59 r dependence Substance abuser alcoholism, childhood-onset psychopathology, 109:245 anorexia and bulimia nervosa, prevalence of drug use in Japanese patients, 109:181 apathy syndrome, cocaine abstinence syndrome, Neuropsychiatric Inventory Apathy Subscale, 109:97 childhood-onset psychopathology, alcoholism, 109:245 childhood-onset psychopathology, opioid dependence, 109:245 cocaine abstinence syndrome, apathy syndrome, Neuropsychiatric Inventory Apathy Subscale, 109:97 cocaine dependence, African-American sample, impulsivity and aggression, serotonin transporter polymorphisms, 110:103 eating disorders, prevalence of drug use in Japanese patients, 109:181

339

genetics, serotonin transporter polymorphisms, impulsivity and aggression, African-American cocaine-dependent sample, 110:103 impulsivity and aggression, serotonin transporter polymorphisms, African-American cocaine-dependent sample, 110:103 Neuropsychiatric Inventory Apathy Subscale, cocaine abstinence syndrome, 109:97 opioid dependence, childhood-onset psychopathology, 109:245 personality, impulsivity and aggression, African-American cocaine-dependent sample, serotonin transporter polymorphisms, 110:103 serotonin transporter polymorphisms, impulsivity and aggression, African-American cocaine-dependent sample, 110:103 Suicide aggression and impulsivity, 5-hydroxyindoleacetic acid in cerebrospinal fluid, 113:193 cholesterol, psychiatric inpatients with and without suicide attempts, Temperament and Character Inventory, 112:83 depressive outpatients, suicidal ideation, lack of seasonality, 112:187 Eysenck Personality Questionnaire, neuroticism, family history of suicide, 110:87 family history of suicide, Eysenck Personality Questionnaire, neuroticism, 110:87 neuroticism, Eysenck Personality Questionnaire, family history of suicide, 110:87 novelty seeking, psychiatric inpatients with and without suicide attempts, cholesterol, 112:83 personality, novelty seeking, psychiatric inpatients with and without suicide attempts, Temperament and Character Inventory, 112:83 season of birth, birth during peak flu season, Southern vs. Northern Hemispheres, 112:89 seasonality, suicidal ideation in psychiatric outpatients, 112:187 serotonin, 5-hydroxyindoleacetic acid in cerebrospinal fluid, aggression and impulsivity, 113:193 suicidal ideation, seasonality, 112:187 Temperament and Character Inventory, novelty Seeking, cholesterol, psychiatric inpatients with and without suicide attempts, 112:83 Tardive dyskinesia genetics, schizophrenia, serotonin, 5-HT6 receptor gene polymorphism, 110:97 schizophrenia, serotonin, 5-HT6 receptor gene polymorphism, 110:97 Temperament and Character Inventory. child rearing effects on personality traits, Parental Bonding Instrument, 111:55 children, factor analysis, preschool version of Temperament and Character Inventory, cholesterol, novelty seeking, psychiatric inpatients with and without suicide attempts, 112:83

340

Subject Index

depressive disorder, personality changes with recovery, 109:17 outcome, personality changes with recovery from depression, 109:17 personality changes with recovery, depressive disorder, 109:17 preschool version of Temperament and Character Inventory, children, factor analysis, suicide, cholesterol, novelty seeking, psychiatric inpatients with and without suicide attempts, 112:83 Testosterone antisocial personality, rapists and child molesters, 110:239 sexual offenders, antisocial personality, rapists and child molesters, 110:239 Thrombin depressive disorder, GTPase activity in platelet membranes, guanine nucleotide-binding regulatory proteins, 112:111 GTPase activity in platelet membranes, schizophrenia, depressive disorder, guanine nucleotide-binding regulatory proteins, 112:111 guanine nucleotide-binding regulatory proteins, schizophrenia, depressive disorder, GTPase activity in platelet membranes, 112:111 schizophrenia, GTPase activity in platelet membranes, guanine nucleotide-binding regulatory proteins, 112:111 Thyroxine cognition, effects of supraphysiological doses on function as assessed with neuropsychological test battery, 110:117 Transcranial magnetic stimulation depressive disorder, effect of subthreshold stimulation course, electroencephalography, 113:245 electroencephalography, depressive disorder, effect of subthreshold stimulation course, 113:245 Traumatic brain injury alcoholism, associated with preexisting brain injury, Northern Finland Birth Cohort Study, 113:217 criminality, associated with preexisting brain injury, Northern Finland Birth Cohort Study, 113:217 epidemiology, Northern Finland Birth Cohort Study, 113:217

mental disorders, associated with preexisting brain injury, Northern Finland Birth Cohort Study, 113:217 Trichotillomania immune activation, interleukin-6 levels in cerebrospinal fluid, 112:257 interleukin-6, cerebrospinal fluid levels, immune activation, 112:257 Tryptophan depletion test insomnia, polysomnography, REM sleep, sleep continuity, 109:129 polysomnography, insomnia, REM sleep, sleep continuity, 109:129 sleep, insomnia, polysomnography, 109:129 Vesicular monoamine transporter depressive disorder, density in platelets of untreated patients, 112:251 Vision cognition, motion perception and working memory, schizophrenia, 111:125 cognition, visual psychophysical tests and neuropsychological function, schizophrenia, 111:125 motion perception and working memory, schizophrenia, 111:125 posttraumatic stress disorder, visuospatial copying tasks, 112:263 schizophrenia, motion perception and working memory, 111:125 schizophrenia, visual psychophysical tests and neuropsychological function, 111:125 visual psychophysical tests and neuropsychological function, motion perception and working memory, schizophrenia, 111:125 visuospatial copying tasks, posttraumatic stress disorder, 112:263 Yale-Brown Obsessive-Compulsive Scale factor analysis, dimensional structure, 109:193